CareMax (CMAXQ) 10-K/A 29 Mar 23 2021 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 11, 2022	Jun. 30, 2021
Document Information [Line Items]
Document Type	10-K/A
Amendment Flag	true
Amendment Description	CareMax, Inc. (the “Company”) is filing this Amendment No. 2 on Form 10-K/A for the year ended December 31, 2021 (this “Form 10-K/A”).  This Form 10-K/A amends the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (“SEC”) on March 16, 2022, as amended by the Amendment No. 1 to the Annual Report on Form 10-K/A, as filed with the SEC on May 2, 2022 (collectively, the “Amended Report”). This Form 10-K/A is being filed to restate the Company’s Consolidated Financial Statements for the year ended December 31, 2021. The restatement reflects a correction of the classification of the equity consideration issued to the Company's real estate advisor in July 2021 from prepaid expenses to other assets. See Note 2 to the Consolidated Financial Statements included in this Form 10-K/A for further information regarding the restatement.
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Registrant Name	CareMax, Inc.
Entity Central Index Key	0001813914
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity File Number	001-39391
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-0992224
Entity Address, Address Line One	1000 NW 57 Court
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33126
City Area Code	786
Local Phone Number	360-4768
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 687,516,271
Entity Interactive Data Current	Yes
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	Documents Incorporated by Reference None.
Auditor Name	WithumSmith+Brown, PC
Auditor Firm ID	100
Auditor Location	Red Bank, New Jersey
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		87,367,972
Title of 12(b) Security	Class A common stock, par value $0.0001 per share
Trading Symbol	CMAX
Security Exchange Name	NASDAQ
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		0
Warrants
Document Information [Line Items]
Title of 12(b) Security	Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol	CMAXW
Security Exchange Name	NASDAQ

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash	$ 47,917	$ 4,934
Accounts receivable, net	41,998	9,395
Inventory	550	15
Prepaid expenses	3,786	183
Risk settlements due from providers	539	80
Due from related parties		274
Total Current Assets	94,790	14,881
Property and equipment, net	15,993	4,796
Goodwill	464,566	10,068
Intangible assets, net	59,811	8,575
Deferred debt issuance costs	1,972
Other assets	15,960	183
Total Assets	653,092	38,503
CURRENT LIABILITIES
Accounts payable	3,110	1,044
Accrued expenses	8,686	2,572
Accrued interest payable	4	149
Risk settlements due to providers	196	643
Current portion of long-term debt	6,275	1,004
Due to related parties		39
Other current liabilities	3,687
Total Current Liabilities	21,959	5,451
Derivative warrant liabilities	8,375
Long-term debt, less current portion	110,960	26,325
Other liabilities	6,428
Total Liabilities	147,722	31,776
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS'/MEMBER'S EQUITY
Class A common stock ($0.0001 par value; 250,000,000 shares authorized; 87,367,972 shares issued and outstanding at December 31, 2021)	9
Additional paid-in-capital	505,327
Retained earnings	33
Member units (no par value, 200 authorized, issued and outstanding at December 31, 2020)		223
Members' equity		6,504
Total Stockholders'/Members' Equity	505,370	6,727
Total Liabilities and Stockholders'/Members' Equity	$ 653,092	$ 38,503

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical)	Dec. 31, 2020 $ / shares shares
Units par value | $ / shares	$ 0
Units authorized	200
Units issued	200
Units outstanding	200

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue
Total revenue	$ 295,762,000	$ 103,421,000
Operating Expenses
External provider costs	206,747,000	66,050,000
Cost of care	57,566,000	17,373,000
Sales and marketing	4,955,000	1,067,000
Corporate, general and administrative	40,579,000	7,748,000
Depreciation and amortization	13,216,000	1,501,000
Acquisition related costs	1,522,000	0
Total operating expenses	324,585,000	93,739,000
Operating (loss) income	(28,822,000)	9,682,000
Interest (expense), net	(4,492,000)	(1,659,000)
Gain on remeasurement of warrant liabilities	20,757,000	0
Gain on remeasurement of contingent earnout liabilities	5,794,000	0
Loss on disposal of fixed assets, net	(50,000)	0
Gain (loss) on extinguishment of debt, net	1,630,000	(451,000)
Other expenses, net	(1,333,000)	0
Income (loss) before income tax	(6,516,000)	7,572,000
Income tax provision	159,000	0
Net (loss) income	(6,675,000)	7,572,000
Net (loss) income attributable to non-controlling interest	0	(29,000)
Net (loss) income attributable to controlling interest	(6,675,000)	7,601,000
Net (loss) income attributable to CareMax, Inc. Class A common stockholders	$ (6,675,000)	$ 7,601,000
Weighted average basic shares outstanding	52,620,980	10,796,069
Weighted average diluted shares outstanding	52,620,980	10,796,069
Net (loss) income per share
Basic	$ (0.13)	$ 0.70
Diluted	$ (0.13)	$ 0.70
Medicare
Revenue
Total revenue	$ 233,282,000	$ 103,051,000
Medicaid
Revenue
Total revenue	46,493,000	0
Other Revenue
Revenue
Total revenue	$ 15,987,000	$ 370,000

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS'/MEMBERS' EQUITY - USD ($) $ in Thousands	Total	Effect of Business Combination	IMC Effect of Business Combination	SMA	DNF	BIX and Advantis	Common Stock Class A Common Stock	Common Stock Class A Common Stock Effect of Business Combination	Common Stock Class A Common Stock IMC Effect of Business Combination	Common Stock Class A Common Stock SMA	Common Stock Class A Common Stock DNF	Common Stock Class A Common Stock BIX and Advantis	Additional Paid-in-Capital	Additional Paid-in-Capital Effect of Business Combination	Additional Paid-in-Capital IMC Effect of Business Combination	Additional Paid-in-Capital SMA	Additional Paid-in-Capital DNF	Additional Paid-in-Capital BIX and Advantis	Total Controlling Interest	Total Controlling Interest Effect of Business Combination	Retained Earnings / (Accumulated Deficit)	Retained Earnings / (Accumulated Deficit) Effect of Business Combination	Noncontrolling Interest
Beginning balance at Dec. 31, 2019	$ 4,946																		$ 5,160				$ (214)
Net income (loss)	7,572																		7,601				(29)
Purchase of non-controlling interest ownership	(2,100)																		(2,100)
Change in ownership due to change in non-controlling interest																			(243)				243
Distributions	(3,691)																		(3,691)
Ending balance at Dec. 31, 2020	6,727																		6,727				$ (260)
Net income (loss)	(6,675)
Net loss prior to business combination	(5,185)																		$ (5,185)
Reverse recapitalization		$ (186,783)						$ 3						$ (186,767)						$ (1,542)		$ 1,523
Reverse recapitalization (in shares)								28,764,819
Equity consideration issued to acquire company			$ 155,347	$ 5,027	$ 26,072	$ 2,231			$ 1						$ 155,346	$ 5,027	$ 26,072	$ 2,231
Equity consideration issued to acquire company (in shares)									10,412,023	384,615	2,741,528	293,987
Shares issued for holdback		821												821
Shares issued for holdback (in shares)								71,000
Contingently issuable stock to CMG Sellers and IMC Parent - First Share Price Trigger on Earnout Shares	39,110						$ 1						$ 39,109
Contingently issuable stock to CMG Sellers and IMC Parent - First Share Price Trigger on Earnout Shares (in shares)							3,200,000
Reclassification of contingent consideration previously liability classified	45,088												45,088
Proceeds from the sale of Class A common stock, net of offering costs	6,650	$ 397,529						$ 4					6,650	$ 397,525
Proceeds from the sale of Class A common stock, net of offering costs (in shares)							500,000	41,000,000
Stock compensation expense	1,341												1,341
Series A Warrants issued under the Advisory Agreement	12,883												12,883
Net loss after business combination	(1,490)																				$ (1,490)
Ending balance at Dec. 31, 2021	$ 505,370						$ 9						$ 505,327								$ 33
Ending balance (in shares) at Dec. 31, 2021							87,367,972

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOW - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss)/Income	$ (6,675,000)	$ 7,572,000
Adjustments to reconcile net (loss)/income to net cash (Used in) provided by operating activities:
Depreciation expense	2,813,000	858,000
Amortization expense	10,402,000	643,000
Amortization of debt issuance costs	866,000	177,000
Stock compensation expense	1,341,000	0
Change in fair value of warrant liabilities	(20,757,000)	0
Gain on fair value change of contingent earnout shares liability	(5,794,000)	0
(Gain) loss on extinguishment of debt	(1,630,000)	451,000
Other Non-cash, net	331,000	0
Changes in operating assets and liabilities:
Accounts receivable	(3,836,000)	(4,208,000)
Inventory	(85,000)	(5,000)
Prepaid expenses	(768,000)	6,000
Risk settlements due from/due to providers	(459,000)	248,000
Due to/from related parties	235,000	(146,000)
Other assets	(1,501,000)	12,000
Accounts payable	(984,000)	(686,000)
Accrued expenses	1,216,000	394,000
Other liabilities	1,574,000	0
Accrued interest	(145,000)	0
Net Cash (Used In)/Provided by Operating Activities	(23,856,000)	5,316,000
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(3,990,000)	(2,151,000)
Acquisition of businesses	(309,707,000)	(2,566,000)
Acquisition of intangible assets	(2,882,000)	0
Asset purchase agreement holdback payment	0	(329,000)
Purchase of noncontrolling interest ownership	0	(1,897,000)
Net Cash Used in Investing Activities	(316,579,000)	(6,942,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Borrowings under revolving loan commitment	0	4,075,000
Loan from Paycheck Protection Program	0	2,164,000
Proceeds from issuance of Class A common stock	415,000,000	0
Issuance costs of Class A common stock	(12,471,000)	0
Reverse recapitalization	(108,435,000)	0
Proceeds from borrowings on long-term debt and credit facilities	125,000,000	0
Principal payments on long-term debt	(27,711,000)	(425,000)
Payment of deferred financing costs	(7,478,000)	0
Payment of debt prepayment penalties	(487,000)	0
Distributions to members	0	(3,691,000)
Net Cash Provided by Financing Activities	383,418,000	2,123,000
NET INCREASE IN CASH	42,983,000	497,000
Cash - Beginning of Period	4,934,000	4,438,000
CASH - END OF PERIOD	47,917,000	4,934,000
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Equity consideration issued in acquisitions	188,678,000	0
Contingent consideration issued in business combination	38,348,000	0
Purchase of non-controlling interest through accounts payable	0	203,000
Payroll Protection Program loan forgiveness	2,164,000	0
Equity/Warrant consideration issued under the Advisory Agreement	14,533,000	0
SUPPLEMENTAL DISCLOSURES OF CASH ACTIVITIES:
Cash paid for interest	4,423,000	1,251,000
Acquisition of business financed through deferred consideration	0	450,000
Purchase of property and equipment through long-term debt	0	50,000
Debt issuance and interest costs paid through long-term debt	0	399,000
Extinguishment of long-term debt through new debt proceeds	0	2,500,000
Acquisition of business financed through long-term debt	$ 0	$ 6,051,000

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1. DESCRIPTION of business CareMax Inc. (“CareMax” or the “Company”), f/k/a Deerfield Healthcare Technology Acquisitions Corp. (“DFHT”), a Delaware corporation, was originally formed in July 2020 as a publicly traded special purpose acquisition company for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination involving one or more businesses. CareMax is a technology-enabled care platform providing high-quality, value-based care and chronic disease management through physicians and health care professionals committed to the overall health and wellness continuum of care for its patients. As of December 31, 2021, Company operated 45 wholly owned, multi-specialty medical centers in Florida that offer a comprehensive suite of healthcare and social services, and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States. The Business Combination On December 18, 2020, DFHT entered into a Business Combination Agreement (the “Business Combination Agreement”) with CareMax Medical Group, L.L.C., a Florida limited liability company (“CMG”), the entities listed in Annex I to the Business Combination Agreement (the “CMG Sellers”), IMC Medical Group Holdings, LLC, a Delaware limited liability company (“IMC”), IMC Holdings, LP, a Delaware limited partnership (“IMC Parent”), and Deerfield Partners, L.P. (“Deerfield Partners”). The Business Combination (as defined below) was approved by DFHT’s stockholders and closed on June 8, 2021 (the “Closing Date”), whereby DFHT acquired 100 % of the equity interests inCMG and 100 % of the equity interests in IMC, with CMG and IMC becoming wholly owned subsidiaries of DFHT. Immediately upon completion (the “Closing”) of the transactions contemplated by the Business Combination Agreement and the related financing transactions (the “Business Combination”), the name of the combined company was changed to CareMax, Inc. At the Closing, the CMG Sellers and IMC Parent were paid consideration valued in the aggregate at approximately $ 364 million and $ 250 million respectively, less repayment of net debt and further subject to the purchase price adjustments set forth in the Business Combination Agreement (the “Closing Consideration”). The net Closing Consideration was comprised of 68 % ($ 229.4 million) and 45 % ($ 85.2 million) in cash for the CMG Sellers and IMC Parent, respectively, with the remainder of the Closing Consideration comprised of 10,796,069 and 10,412,023 shares of Class A common stock of the Company, par value $ 0.0001 per share (“Class A Common Stock”), issued to the CMG Sellers and IMC Parent, respectively, at a reference price of $ 10.00 per share. The Business Combination Agreement also provides that an additional 3,500,000 and 2,900,000 shares of Class A Common Stock (the “Earnout Shares”) are payable after the Closing to the CMG Sellers and IMC Parent, respectively, upon the satisfaction of certain conditions (see Note 8 – Stockholders' Equity). Also at the Closing, DFHT, DFHTA Sponsor LLC (the “Sponsor”), O.M. Investment Group, Inc. (“O.M.”), in its capacity as representative of the CMG Sellers, and Continental Stock Transfer & Trust Company, in its capacity as escrow agent ( “Continental”), entered into an escrow agreement (the “CMG Escrow Agreement”), and DFHT, the Sponsor, IMC Parent and Continental entered into an escrow agreement (the “IMC Escrow Agreement” and together with the CMG Escrow Agreement, the “Escrow Agreements”). Pursuant to the terms of the CMG Escrow Agreement and the IMC Escrow Agreement, DFHT deposited $ 0.5 million and $ 1.0 million, respectively, into adjustment escrow accounts (the “Adjustment Escrow Amounts”) for the purpose of securing certain post-closing adjustment obligations of the CMG Sellers and IMC Parent, respectively. Of such $ 0.5 million securing the post-closing adjustment obligations of the CMG Sellers, 68 % ($ 340,000 ) was in cash and 32 % was in 16,000 shares of Class A Common Stock, and of such $ 1.0 million securing the post-closing adjustment obligations of IMC Parent, 45 % ($ 450,000 ) was in cash and 55 % was in 55,000 shares of Class A Common Stock (such shares collectively, the “Adjustment Escrow Shares”). Following the date on which the Closing Consideration is finally determined pursuant to the Business Combination Agreement, all or a portion of the applicable Adjustment Escrow Amounts and Adjustment Escrow Shares will either be released to the CMG Sellers or to IMC Parent, as applicable, or to the Company in accordance with certain adjustment mechanisms in the Business Combination Agreement. Immediately following the Closing, all of the 3,593,750 issued and outstanding shares of Class B common stock of the Company, par value $ 0.0001 per share (“Class B Common Stock”), automatically converted, on a one-for-one basis, into shares of Class A Common Stock in accordance with DFHT’s second amended and restated certificate of incorporation. Unless the context otherwise requires, “the Company,” “we,” “us,” and “our” refer, for periods prior to the completion of the Business Combination, to CMG and its subsidiaries, and, for periods upon or after the completion of the Business Combination, to CareMax, Inc. and its subsidiaries.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The consolidated financial statements include the account of CareMax Inc. and its wholly owned subsidiaries (collectively "CareMax" or "the Company"). Intercompany accounts and transactions have been eliminated. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for annual financial information and in accordance with the instructions to Form 10-K/A and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). In the opinion of management, the accompanying consolidated financial statements include all adjustments of a normal recurring nature, which are necessary for a fair presentation of financial position, operating results and cash flows for the periods presented. Pursuant to the Business Combination, the acquisition of CMG by DFHT was accounted for as a reverse recapitalization in accordance with GAAP (the “Reverse Recapitalization”). Under this method of accounting, DFHT was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of CMG issuing equity for the net assets of DFHT, accompanied by a recapitalization. The net assets of DFHT are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of CMG. Further, CMG was determined to be the accounting acquirer in the acquisition of IMC (the “IMC Acquisition”), as such, the acquisition is considered a business combination under Accounting Standards Codification ("ASC") Topic 805, " Business Combinations ," and was accounted for using the acquisition method of accounting. CareMax recorded the fair value of assets acquired and liabilities assumed from IMC.The presented financial information for the twelve months ended December 31, 2021 includes the financial information and activities for (i) IMC for the period from June 8, 2021 to (and including) December 31, 2021 (206 days), (ii) SMA (as defined in Note 3 - Acquisitions) for the period from June 18, 2021 to (and including) December 31, 2021 (196 days) and (iii) DNF (as defined in Note 3 - Acquisitions) for the period from September 1, 2021 to (and including) December 31, 2021 (121 days). Unless otherwise noted, information for periods prior to the Closing of Business Combination reflects the financial information of CMG only. The consolidated financial statements include the accounts and operations of the Company. All intercompany accounts and transactions have been eliminated. Restatement of Previously Reported Financial Statements In conjunction with the Company's close process for the year ended December 31, 2022, management identified an error related to classification of equity consideration issued to the Company's real estate advisor in July 2021 (the "Prepaid Asset"). The Prepaid Asset was previously presented as part of the Company's short-term assets, in prepaid expenses. The Company determined that because the Prepaid Asset relates to services that are performed by the real estate advisor over multiple years, the Prepaid Asset should be recorded in other assets, except for the portion that represents the Prepaid Asset amortization expense expected to be recognized during the next twelve months following a given period. The following table reflects the impact of the restatement to the specified line items presented in the Company's previously reported consolidated balance sheet as of December 31, 2021: (in thousands) As Previously Reported Adjustment As Restated ASSETS Affected financial statement line items Prepaid expenses 17,040 ( 13,254 ) 3,786 Total Current Assets $ 108,044 $ ( 13,254 ) $ 94,790 Other assets 2,706 13,254 15,960 There was no impact on the condensed consolidated statement of operations, statements of changes in stockholders'/members' equity or statement of cash flows. The accompanying applicable Notes have been updated to reflect the restatement described above. Segment Financial Information The Company’s chief operating decision maker regularly reviews financial operating results on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company identifies operating segments based on this review by its chief operating decision maker and operates in and reports as a single operating segment, which is to care for its patients’ needs. For the periods presented, all of the Company’s long-lived assets were located in the United States, and all revenue was earned in the United States. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The areas where significant estimates are used in the accompanying financial statements include, but are not limited to, purchase price allocations, including fair value estimates of intangibles and contingent consideration; the valuation of and related impairment recognitions of long-lived assets; the valuation of the derivative warrant liabilities; the estimated useful lives of fixed assets and intangible assets, including internally developed software; settlements related to revenue and the revenue accrual and accrued expenses. Actual results could differ from those estimates. Emerging Growth Company Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to nonemerging growth companies, but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Additionally, as an emerging growth company, the Company is exempt from the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, and the Company’s independent registered public accounting firm is not required to evaluate and report on the effectiveness of internal control over financial reporting. Acquisitions The Company accounts for business combinations under the acquisition method of accounting, in accordance with ASC Topic 805, Business Combinations , which requires assets acquired and liabilities assumed to be recognized at their fair values on the acquisition date. Any excess of the fair value of purchase consideration over the fair value of the assets acquired less liabilities assumed is recorded as goodwill. The fair values of the assets acquired, and liabilities assumed are determined based upon the valuation of the acquired business and involves management making significant estimates and assumptions. Revenue Recognition Since capitated revenue is received regardless of whether services are performed, the performance obligation is the completion of enrollment of the patient and providing access to care. Fee-for-service revenue generally relates to contracts with patients in which our performance obligation is to provide healthcare services to the patients. Revenues are recorded during the period our obligations to provide healthcare services are satisfied. Medicare Risk-based and Medicaid Risk-based revenue consists primarily of capitated fees for medical services provided by us under capitated arrangements directly made with various Medicare Advantage and Medicaid managed care payors. The Company receives a fixed fee per patient under what is typically known as a “risk contract.” Risk contracting, or full risk capitation, refers to a model in which the Company receives from the third-party payor a fixed payment of At-risk premium less an administrative charge for reporting on enrollees on a per patient per month basis (“PPPM” payment) for a defined patient population, and the Company is then responsible for providing healthcare services required by that patient population. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers. The Company’s payor contracts generally have a term of one year or longer, but the contracts between the enrolled members (our customers) and the payor are one calendar year or less. In general, the Company considers all contracts with customers (enrolled members) as a single performance obligation to stand ready to provide managed healthcare services. The Company identified that contracts with customers for capitation arrangements have similar performance obligations and therefore groups them into one portfolio. This performance obligation is satisfied as the Company stands ready to fulfill its obligation to enrolled members. Settlements with third-party payors for retroactive adjustments due to capitation risk adjustment, or claim audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the following factors: • Geography of the service location • Demographics of members • Health needs of members • Method of reimbursement (capitation or fee for service) • Enrollment changes • Rate changes; and • For fee for service activities, the payors (for example, Medicare, Medicaid, commercial insurance, patient) which have different reimbursement/payment methodologies. The Company has elected the practical expedient allowed under ASC 606-10-32-18, “Revenue from Contracts with Customers-The Existence of a Significant Financing Component in the Contract,” and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Company’s expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. The Company has applied the practical expedient provided by ASC 340-40-25-4, “Other Assets and Deferred Costs,” and all incremental customer contract acquisition costs are expensed as they are incurred as the amortization period of the asset that the Company otherwise would have recognized is one year or less in duration. For the twelve months ended December 31, 2021 and 2020, substantially all of the revenue recognized by the Company was from goods and services, namely, providing access to physicians and wellness centers. Other Revenue Other revenue includes professional capitation payments. These revenues are a fixed amount of money per patient per month paid in advance for the delivery of primary care services only, whereby the Company is not liable for medical costs in excess of the fixed payment. Capitated revenues are typically prepaid monthly to the Company based on the number of patients selecting us as their primary care provider. Our capitated rates are fixed, contractual rates. Incentive payments for Healthcare Effectiveness Data and Information Set (“HEDIS”) and any services paid on a fee for service basis by a health plan are also included in other revenue. Other revenue also includes ancillary fees earned under contracts with certain payors for the provision of certain care coordination and other care management services. These services are provided to patients covered by these payors regardless of whether those patients receive their care from our affiliated medical groups. Revenue for primary care service for patients in a partial risk or up-side only contracts are reported in other revenue. Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and accounts receivable. The Company’s cash balances with individual banking institutions are in excess of federally insured limits from time to time. The Company believes it is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash and cash equivalents. Anthem, Inc. ("Anthem") represented approximately 27 % and 100 % of the Company’s accounts receivable balance as of December 31, 2021 and December 31, 2020, respectively. Anthem represented 35 % and 93 % of the Company’s revenues for the three months ended December 31, 2021 and 2020 and 48 % and 96 % of the Company’s revenues for the twelve months ended December 31, 2021 and 2020 , respectively. Accounts Receivable Accounts receivable are carried at the amounts the Company deems collectible. Accordingly, an allowance is provided based on credit losses expected over the contractual term. Accounts receivable are written off when they are deemed uncollectible. As of December 31, 2021 and 2020, the Company believes no allowance is necessary. Fair Value of Financial Instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: Level 1 - defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets. Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Derivative Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants and contingent consideration, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 “Distinguishing Liabilities from Equity,” and ASC 815-15, “Derivatives and Hedging - Embedded Derivatives. ” The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company issued 2,875,000 common stock warrants in connection with DFHT's initial public offering (the “IPO”) (the “Public Warrants”). Simultaneously with the closing of the IPO, DFHT consummated the private placement of 2,916,667 common stock warrants (the “Private Placement Warrants”). The Public Warrants and Private Placement Warrants are accounted for as derivative warrant liabilities in accordance with ASC 815-40, “ Derivatives and Hedging - Contracts in an Entity's Own Equity .” Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s consolidated statement of operations. The fair value of the Public Warrants and Private Placement Warrants was initially measured at fair value using a Monte Carlo simulation model and subsequently, the fair value of the Private Placement Warrants has been estimated using a Monte Carlo simulation model at each measurement date. The fair value of Public Warrants issued in connection with the IPO has subsequently been measured based on the listed market price of such warrants. In connection with the Business Combination, up to 6,400,000 shares of Class A Common Stock become issuable under certain circumstances to IMC Parent and the CMF Sellers as contingent consideration (the “Contingent Consideration”). The Contingent Consideration was accounted for as derivative warrant liabilities in accordance with ASC 815-40, “ Derivatives and Hedging - Contracts in an Entity's Own Equity .” Accordingly, the Company recognized the Contingent Consideration as liabilities at fair value in the second quarter of 2021 following a restatement of the Company’s unaudited condensed consolidated financial statements for the periods ended June 30, 2021 and September 30, 2021 (see Note – Stockholders Equity – Contingent Consideration for further information). The liabilities were subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s consolidated statement of operations. On July 9, 2021, the First Share Price Trigger (as defined below) was achieved, and the remaining Contingent Consideration was re-assessed and determined to be indexed to the Company's own equity, resulting in equity classification under ASC 815-40 “ Derivatives and Hedging - Contracts in an Entity's Own Equity .” The remaining Contingent Consideration was recorded at fair value on July 9, 2021, the date of the event that caused the reclassification. Changes in the fair value upon reclassification from liability to equity were recorded in earnings. See Note 8 – Stockholders Equity – Contingent Consideration for further information. Goodwill and Intangible Assets Goodwill represents the excess of consideration transferred in excess of the fair value of net assets acquired through business acquisitions. Pursuant to ASC 350, “Intangibles – Goodwill and Other,” we review goodwill annually in the fourth quarter or whenever significant events or changes indicate the possibility of impairment. For purposes of the annual goodwill impairment assessment, the Company has identified a single reporting unit. The most recently completed impairment test of goodwill was performed in the fourth quarter of 2021, and it was determined that the fair value of goodwill was in excess of the carrying value, therefore no impairment was necessary. Intangible assets with a finite useful life are amortized over their useful lives. We review the recoverability of any long-lived intangible assets whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. Impairment of Long-lived Assets Long-lived assets, such as equipment, improvements, and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the use and eventual disposition of the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value. Property and Equipment Property and equipment is recorded at cost. Maintenance and repairs are charged to expense as incurred. Depreciation is provided over the estimated useful life of each class of depreciable asset and is computed on the straight-line method. Leasehold improvements are depreciated over the lesser of the length of the related lease plus any renewal options or the estimated life of the asset. A summary of estimated useful lives is as follows: Leasehold Improvements 15 to 39 Years Furniture and Equipment 5 to 7 Years Vehicles 5 Years Software 3 Years Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “ Income Taxes .” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2021 and December 31, 2020 . The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. External Provider Costs External Provider Costs include capitation payments and fee for service claims paid, claims in process and pending, and an estimate of unreported claims and charges by physicians, hospitals, and other health care providers for services rendered to enrollees during the period. Changes to prior-period estimates of medical expenses are reflected in the current period. Share-Based Compensation Expense The Company periodically issues Restricted Stock Units ("RSU's"), Performance Share Units ("PSUs"), and Stock Options ("Options") as share-based compensation to employees and non-employees in non-capital raising transactions for services. The Company accounts for such grants issued and vesting based on FASB ASC 718, Compensation – Stock Compensation (Topic 718), whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered. The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting Measurement of share-based payment transactions with non-employees are recognized as compensation expense in the financial statements based on their fair values at grant date. That expense is recognized over the period during which a non-employees or consultant is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The fair value of the Company’s Options, RSUs and PSUs are estimated using the Black-Scholes-Merton Option Pricing model and a Monte Carlo simulation, respectively, which use certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or stock, and future dividends. Compensation expense for Options , RSUs and PSUs are recorded based upon the values derived from the Black-Scholes-Merton Option Pricing model and the Monte Carlo simulation, respectively. The assumptions used in the Black-Scholes-Merton Option Pricing model and Monte Carlo Simulation(s) could materially affect compensation expense recorded in future periods. The assumptions used in the model and related impact are discussed in Note 8 - Stockholders Equity . Net Income (Loss) Per Share Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. The Company follows the provisions of ASC Topic 260, Earnings Per Share , for determining whether contingently issuable shares are included for purposes of calculating net income (loss) per share and determining whether instruments granted in equity-based compensation arrangements are participating securities for purposes of calculating net income (loss) per share. See Note 9 - Net Income (Loss) Per Share. Recent Accounting Pronouncements Not Yet Adopted In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, " Leases " (“ASU 2016-02”), which amended the accounting for leases, requiring lessees to recognize most leases on their balance sheet with a right-of-use asset and a lease liability. Leases will be classified as either finance or operating leases, which will impact the expense recognition of such leases over the lease term. ASU 2016-02 also modifies the lease classification criteria for lessors and eliminates some of the real estate leasing guidance previously applied for certain leasing transactions. In June 2020, the FASB issued ASU 2020-05, “ Revenue from Contracts with Customers and Leases ,” that deferred the required effective date for non-issuers to fiscal years beginning after December 15, 2021 and to interim periods within fiscal years beginning after December 15, 2022. The Company adopted ASU 2016-02 on January 1, 2022. Because of the number of leases the Company utilizes to support its operations, the adoption of ASU 2016-02 is expected to have a significant impact on the Company’s financial position and results of operations. The total future estimated gross annual lease payments are $ 106.7 million as of December 31, 2021 . We expect this standard to increase our total assets and total liabilities by approximately 12 % percent. We do not expect the standard to have a material impact on our results of operations. In preparation for the adoption of the standard, we have procured a third-party software to track and manage our leases, loaded lease data into the software, authored our accounting policy, trained our business units on the new standard and policy and the use of the software, and modified our control environment accordingly. We have not experienced significant issues in our implementation process. In June 2016, the FASB issued ASU 2016-13, " Financial Instruments – Credit Losses (Topic 326) : Measurement of Credit Losses on Financial Instruments" (“ASU 2016-13”). ASU 2016-13 introduced a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The guidance became effective for us beginning January 1, 2022. The new current expected credit losses model generally calls for the immediate recognition of all expected credit losses and applies to loans, accounts and trade receivables as well as other financial assets measured at amortized cost, loan commitments and off-balance sheet credit exposures, debt securities and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The new guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available for sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. The Company adopted this standard on January 1, 2022 and does not believe adoption will have a material effect on its consolidated financial statements. In January 2020, the FASB issued ASU 2020-01, " Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323) , and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815" (“ASU 2020-01”). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact the adoption of ASU 2020-01 will have on its consolidated financial statements. In March 2020, the FASB issued guidance to provide temporary optional expedients and exceptions through December 31, 2022 to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing Rate (SOFR). The amendments are effective for all entities from the beginning of an interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The Company is currently evaluating the effect the update will have on its consolidated financial statements and related disclosures. In October 2021, the FASB issued ASU 2021-08, "Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." The ASU improves comparability after business combinations by providing consistent recognition and measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not acquired in a business combination. ASU 2021-08 is effective for the Company on January 1, 2023, with early adoption permitted. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements. We do not expect that any other recently issued accounting guidance will have a significant effect on our consolidated financial statements.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Acquisitions	NOTE 3. ACQUISITIONS Acquisition of IMC On June 8, 2021, the Company acquired 100 % of the equity interests of IMC for total purchase consideration of $ 369.7 million, subject to final closing adjustments. The purchase consideration was comprised of the following (in thousands): Cash consideration (1) $ 172,302 Share consideration (2) $ 155,347 Contingent consideration (3) $ 40,785 Other consideration (4) $ 1,271 (1) Represents cash consideration inclusive of the payment of $ 79.8 million of IMC debt simultaneous with the Closing and the reimbursement of IMC Parent's transaction costs of $ 7.3 million. (2) Represent the issuance of 10,412,023 shares of Class A Common Stock, which shares were issued at a reference price of $ 10.00 per share, but the value of which was $ 14.92 per share, the closing price on the date of the IMC Acquisition. (3) Represents the fair value of equity-classified contingent consideration. (4) Represents the fair value of cash and equity purchase consideration held in escrow pending the finalization of final closing adjustments. The IMC Acquisition was recorded as a business combination under ASC 805 with identifiable assets acquired recorded at their estimated fair values as of the acquisition date. As of December 31, 2021 , we have not finalized the acquisition accounting related to the IMC Acquisition and these amounts represent preliminary values. The allocation of the purchase price may be modified up to one year from the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed. The following table summarizes the purchase consideration and the preliminary fair value of the assets acquired and liabilities assumed ( in thousands ):  Purchase price allocation Cash $ 14,842 Accounts receivable 21,298 Other current assets 1,446 Property, plant, & equipment 6,198 Intangible assets 34,121 Other assets 448 Accounts payable and accrued expenses ( 8,793 ) Long term debt ( 197 ) Other long term liabilities ( 1,898 ) Net Assets Acquired 67,465 Excess of Consideration over Net Assets Acquired 302,240 Total Consideration $ 369,705 Goodwill was recognized as the amount consideration transferred in excess of the fair value of net assets acquired. The goodwill generated is attributable to the assembled workforce and the expected growth and cost synergies and the expected contribution to the Company’s overall strategy. The amount allocated to goodwill and intangible assets is subject to final adjustment to reflect the final valuations. The goodwill recognized that is expected to be deductible for income tax purposes is $ 80.4 million. The fair value associated with definite-lived intangible assets was $ 34.1 million, comprised of $ 33.9 million in risk contracts and $ 263,000 in trademarks. The definite-lived intangible assets will be amortized ranging from one to six years . The Company’s net revenue and loss before income taxes for the twelve months ended December 31, 2021 includes revenues of $ 148.0 million and net income before taxes of $ 4.1 million related to IMC. Acquisition of SMA Entities On June 18, 2021, the Company completed the acquisition of 100 % of the issued and outstanding equity interests of Senior Medical Associates, LLC, a Florida limited liability company (“SMA”), and Stallion Medical Management, LLC, a Florida limited liability company (“the SMA Acquisition”). The purchase consideration was comprised of the following ( in thousands ): Cash consideration (1) $ 52,000 Share consideration (2) $ 5,027 (1) Represents cash consideration of $ 52.0 million inclusive of $ 2.5 million held in escrow and $ 145,000 in SMA seller transaction cost. (2) Represents equity consideration of 384,615 shares of Class A Common Stock valued at $ 5.0 million based on the June 18, 2021 closing price of $ 13.07 . The SMA Acquisition was recorded as a business combination under ASC 805 with identifiable assets acquired and liabilities assumed liabilities recorded at their estimated fair values as of the acquisition date. As of December 31, 2021 , we have not finalized the acquisition accounting related to the SMA Acquisition and these amounts represent preliminary values. The allocation of the purchase price may be modified up to one year from the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed. The following table summarizes the consideration paid and the preliminary fair value of the assets acquired and liabilities assumed ( in thousand s):  Purchase price allocation Cash $ 73 Accounts receivable 1,830 Property, plant, & equipment 178 Intangible assets 9,404 Other assets 29 Accounts payable and accrued expenses ( 178 ) Net Assets Acquired 11,336 Excess of Consideration over Net Assets Acquired 45,691 Total Consideration $ 57,027 Goodwill was recognized as the amount consideration transferred in excess of the fair value of net assets acquired. The goodwill is primarily attributed to our assembled workforce, the expected growth and cost synergies and the expected contribution to the Company’s overall strategy. The goodwill recognized that is expected to be deductible for income tax purposes is $ 45.0 million. The Company incurred and expensed acquisition-related transaction costs of $ 682,000 related to the SMA Acquisition that were paid by the Company. The fair value associated with definite-lived intangible assets was $ 9.4 million, comprised of $ 8.7 million in risk contracts, $ 622,000 in non-compete agreements and $ 92,000 in tradenames. The definite-lived intangible assets will be amortized over periods ranging from one to six years . The Company’s net revenue and loss before income taxes for the twelve months ended December 31, 2021 includes revenues of $ 12.0 million and net income before taxes of $ 564,000 related to SMA. Acquisition of DNF On September 1, 2021, the Company acquired 100 % of the assets of Unlimited Medical Services of Florida, LLC, a Florida limited liability company, dba DNF Medical Centers ("DNF"), for total purchase consideration of $ 114.2 million, subject to final closing adjustments (the "DNF Acquisition"). The purchase consideration was comprised of the following ( in thousands ): Cash consideration (1) $ 88,118 Share consideration (2) $ 26,072 (1) Represents cash consideration of $ 88.1 million inclusive of $ 11.0 million held in escrow and $ 242,000 in DNF seller transaction costs. (2) Represents equity consideration of 2,741,528 shares of Class A Common Stock valued at $ 26.1 million based on the September 1, 2021 closing price of $ 9.51 . The DNF Acquisition was recorded as a business combination under ASC 805 with identifiable assets acquired recorded at their estimated fair values as of the acquisition date. As of December 31, 2021 , we have not finalized the acquisition accounting related to the DNF Acquisition and these amounts represent preliminary values. The allocation of the purchase price may be modified up to one year from the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed. The following table summarizes the purchase consideration and the preliminary fair value of the assets acquired ( in thousands ):  Purchase price allocation Accounts receivable $ 3,732 Property, plant, & equipment 3,520 Intangible assets 15,329 Other assets 65 Net Assets Acquired 22,646 Excess of Consideration over Net Assets Acquired 91,544 Total Consideration $ 114,190 Goodwill was recognized as the amount consideration transferred in excess of the fair value of net assets acquired. The goodwill generated is attributable to the assembled workforce and the expected growth and cost synergies and the expected contribution to the Company’s overall strategy. The amount allocated to goodwill and intangible assets is subject to final adjustment to reflect the final valuations. The goodwill recognized that is expected to be deductible for income tax purposes is $ 90.0 million. The Company incurred and expensed acquisition-related transaction costs of $ 1,247,000 related to the DNF Acquisition that were paid by the Company. The fair value associated with definite-lived intangible assets was $ 15.3 million, comprised of $ 13.2 million in risk contracts, $ 1.5 million in non-compete agreements, and $ 638,000 in trademarks. The definite-lived intangible assets will be amortized ranging from one to six years . The Company’s net revenues and loss before income taxes for the twelve months ended December 31, 2021 includes revenue of $ 19.5 million and net loss before income taxes of $ 687,000 related to DNF. Acquisition of Advantis On December 22, 2021, the Company acquired 100 % of the assets of Advantis Physician Alliance, LLC, dba Advantis Medical Centers ("Advantis") for total purchase consideration of $ 11.0 million, subject to final closing adjustments (the "Advantis Acquisition"). The purchase consideration was comprised of the following ( in thousands ): Cash consideration (1) $ 9,865 Share consideration (2) $ 1,107 (1) Represents cash consideration of $ 9.9 million inclusive of $ 900,000 held in escrow and $ 60,000 in Advantis seller transaction cost (2) Represents equity consideration of 145,883 shares of Class A Common Stock valued at $ 1.1 million based on the December 22, 2021 closing price of $ 7.59 . The Advantis acquisition was recorded as a business combination under ASC 805 with identifiable assets acquired recorded at their estimated fair values as of the acquisition date. As of December 31, 2021 , we have not finalized the acquisition accounting related to the Advantis Acquisition and these amounts represent preliminary values. The allocation of the purchase price may be modified up to one year from the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed. The following table summarizes the purchase consideration and the preliminary fair value of the assets acquired ( in thousands) :  Purchase price allocation Accounts receivable $ 242 Property, plant, & equipment 18 Intangible assets 1,064 Other assets 20 Net Assets Acquired 1,344 Excess of Consideration over Net Assets Acquired 9,628 Total Consideration $ 10,972 Goodwill was recognized as the amount consideration transferred in excess of the fair value of net assets acquired. The goodwill generated is attributable to the assembled workforce and the expected growth and cost synergies and the expected contribution to the Company’s overall strategy. The amount allocated to goodwill and intangible assets is subject to final adjustment to reflect the final valuations. The goodwill recognized that is expected to be deductible for income tax purposes is $ 9.6 million. The Company incurred and expensed acquisition-related transaction costs of $ 671,000 related to the Advantis Acquisition that were paid by the Company. The fair value associated with definite-lived intangible assets was $ 1.1 million, comprised of $ 345,000 in risk contracts, $ 544,000 in non-compete agreements, and $ 176,000 in trademarks. The definite-lived intangible assets will be amortized ranging from one to six years . As the acquisition was consummated on December 22, 2021, Advantis did not materially contribute net revenues or net income before income taxes for the twelve months ended December 31, 2021. Acquisition of Business Intelligence & Analytics LLC ("BIX") On December 22, 2021, the Company acquired 100 % of the assets of Business Intelligence & Analytics LLC ("BIX") for total purchase consideration of $ 5.1 million, subject to final closing adjustments (the "BIX Acquisition"). The purchase consideration was comprised of the following ( in thousands ): Cash consideration (1) $ 4,000 Share consideration (2) $ 1,124 (1) Represents cash consideration of $ 4.0 million. (2) Represents equity consideration of 148,104 shares of Class A Common Stock valued at $ 1.1 million based on the December 22, 2021 closing price of $ 7.59 . The BIX Acquisition was recorded as a business combination under ASC 805 with identifiable assets acquired recorded at their estimated fair values as of the acquisition date. As of December 31, 2021 , we have not finalized the acquisition accounting related to the BIX Acquisition and these amounts represent preliminary values. The allocation of the purchase price may be modified up to one year from the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed. The following table summarizes the purchase consideration and the preliminary fair value of the assets acquired ( in thousands) :  Purchase price allocation Intangible assets 289 Net Assets Acquired 289 Excess of Consideration over Net Assets Acquired 4,835 Total Consideration $ 5,124 Goodwill was recognized as the amount consideration transferred in excess of the fair value of net assets acquired. The goodwill generated is attributable to the assembled workforce and the expected growth and cost synergies and the expected contribution to the Company’s overall strategy. The amount allocated to goodwill and intangible assets is subject to final adjustment to reflect the final valuations. The goodwill recognized that is expected to be deductible for income tax purposes is $ 4.8 million. The Company did no t incur or expense material acquisition-related transaction costs that were paid by the Company. The fair value associated with definite-lived intangible assets was $ 289,000 , comprised of $ 235,000 in patents/developed technology, $ 3,000 in trademarks, and $ 35,000 in non-compete agreements. The definite-lived intangible assets will be amortized ranging from one to five years . $ 16,000 in In-Process Research and Development was classified as an indefinite lived intangible asset. As the acquisition was consummated on December 22, 2021, BIX did not materially contribute net revenues or net income before income taxes for the twelve months ended December 31, 2021. Other Acquisitions During the twelve months ended December 31, 2021 , we acquired 100 % of three additional business. The acquisitions were accounted for as business combinations and the overall impact to our consolidated financial statements was not considered to be material. The fair value associated with definite-lived intangible assets from the acquisitions was $ 1.4 million. On a combined basis, the Company incurred and expensed acquisition-related transaction costs of $ 250,000 related to the acquisitions that was paid for by the Company. The total fair value of consideration paid or payable for the three acquisitions was $ 3.7 million.

Reinsurance

Reinsurance	12 Months Ended
	Dec. 31, 2021
Reinsurance Disclosures [Abstract]
Reinsurance	OTE 4. REINSURANCE The Company has acquired insurance on catastrophic costs to limit the exposure on patient losses. Premiums and policy recoveries are reported in external provider costs in the accompanying consolidated statements of operations. The nature of the Company’s stop loss coverage is to limit the benefits paid under one patient. The Company’s stop loss limits are defined within each health plan contract and stop loss purchased from a third party and range from $ 30,000 to $ 200,000 per patient per year. Premium expense incurred was $ 10.9 million for the twelve months ended December 31, 2021 and approximately $ 10.3 million for the twelve months ended December 31, 2020, respectively. Physicians under capitation arrangements typically have stop loss coverage so that a physician’s financial risk for any single member is limited to a maximum amount on an annual basis. The Company monitors the financial performance and solvency of its stop loss providers. However, the Company remains financially responsible for health care services to its members in the event the health plans are unable to fulfill their obligations under stop loss contractual terms. Recoveries recognized were $ 14.7 million for the twelve months ended December 31, 2021 and $ 11.2 million the twelve months ended December 31, 2020 , respectively. Estimated recoveries under stop loss policies are reported within the capitation receivable or amounts due health plans as the counterparty responsible for the payment of the claims and the stop loss is the respective health plan.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	NOTE 5. GOODWILL AND INTANGIBLE ASSETS Goodwill The following table shows changes in the carrying amount of goodwill from December 31, 2020 to December 31, 2021 ( in thousands ): Carrying Amount Balance at December 31, 2020 $ 10,068 Acquired goodwill during the period 454,498 Balance at December 31, 2021 $ 464,566 Intangible Assets The following table summarizes the gross carrying amounts and accumulated amortization of intangible assets by major class ( in thousands ): Gross Carrying Accumulated Net Book Weighted Average December 31, 2021 Risk Contracts $ 64,822 $ ( 9,818 ) $ 55,004 7 Non-compete agreements 4,202 ( 686 ) 3,516 5 Trademarks 1,867 ( 827 ) 1,040 2 Patents/Developed Technology 235 - 235 5 In-Process Research and Development 16 - 16 1 Total $ 71,141 $ ( 11,331 ) $ 59,811 Gross Carrying Accumulated Net Book Weighted Average December 31, 2020 Risk Contracts $ 8,174 $ ( 682 ) $ 7,492 11 Non-compete agreements 1,320 ( 237 ) 1,083 5 Total $ 9,494 $ ( 919 ) $ 8,575 Amortization expense totaled $ 10.4 million for the twelve months ended December 31, 2021 and $ 645,000 for the twelve months ended December 31, 2020, respectively. The estimated amortization expense related to the fair value of acquired intangible assets for each of the succeeding five years and thereafter is ( in thousands ): 2022 $ 15,134 2023 12,234 2024 10,199 2025 8,547 2026 7,616 Thereafter 6,082

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 6. PROPERTY AND EQUIPMENT A summary of property and equipment at December 31, 2021 and December 31, 2020 is as follows ( in thousands ): December 31, 2021 December 31, 2020 Leasehold improvements $ 7,516 $ 2,726 Vehicles 3,711 2,823 Furniture and equipment 5,470 1,983 Software 2,950 - Construction in progress 2,254 360 Total 21,902 7,892 Less: Accumulated depreciation ( 5,909 ) ( 3,096 ) Total Property and equipment, net $ 15,993 $ 4,796 Construction in progress at December 31, 2021 is made up of various leasehold improvements at the Company's medical centers. The Company has a contractual commitment to complete the construction of its Homestead medical center with remaining estimated capital expenditures of $ 500,000 and an estimated opening in 2022. Depreciation expense totaled $ 2.8 million for the twelve months ended December 31, 2021 and $ 858,000 for the twelve months ended December 31, 2020 , respectively

Long Term Debt

Long Term Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Long Term Debt	NOTE 7. LONG TERM DEBT Long-term debt consisted of the following at December 31, 2021 and December 31, 2020 ( in thousands ): December 31, December 31, Secured term loans $ 121,875 $ 24,184 Payroll protection plan - 2,164 Other 65 1,358 Unamortized debt issuance costs ( 4,704 ) ( 377 ) 117,236 27,329 Current portion ( 6,275 ) ( 1,004 ) Long-term portion $ 110,960 $ 26,325 On the Closing Date, the Company entered into a Credit Agreement (as amended, the “Credit Agreement), by and among the Company, Royal Bank of Canada, as Administrative Agent (in such capacity, the “Agent”), Collateral Agent, Swing Line Lender and Issuing Bank; RBC Capital Markets, LLC and Truist Securities, Inc., as Syndication Agents, Joint Lead Arrangers and Joint Book Runners; and certain other banks and financial institutions serving as lenders (collectively with their successors and assigns, the “Lenders”). The Credit Agreement provides for (i) initial term loans in an aggregate principal amount of $ 125.0 million (the “Initial Term Loans”), which were used on the Closing Date to finance the Business Combination and related transaction costs, (ii) a revolving credit facility in an aggregate principal amount of $ 40.0 million for working capital and other general corporate purposes, of which $0 was drawn December 31, 2021 and (iii) a delayed draw term loan facility in an aggregate principal amount of $ 20.0 million, which was available to be drawn from and after the Closing until the six month anniversary of the Closing Date to finance permitted acquisitions and similar permitted investments and of which $ 0 was drawn as of the date of its expiration, or December 8, 2021 (collectively, the “Credit Facilities”). Interest is payable on the outstanding loans under the Credit Facilities based on, at the option of the Company, either: (i) Eurocurrency (with a LIBOR floor of 0.75 % per annum) plus variable spreads ranging from 2.75 % to 3.50 % per annum based on first lien net leverage ratio levels or (ii) the Alternate Base Rate (defined as the highest of (a) the Prime Rate (as defined in the Credit Agreement and established by the Agent), (b) the Federal Funds Rate (as defined in the Credit Agreement) plus 0.50 % per annum, and (c) the LIBOR Quoted Rate (as defined in the Credit Agreement) plus 1.00 % per annum, in each case, with a floor of 1.75 % per annum), plus variable spreads ranging from 1.75 % to 2.50 % per annum based on first lien net leverage ratio levels. Accrued and unpaid interest is payable with respect to LIBOR loans on the last day of the interest period as selected by the Company but no later than three months, and with respect to Alternate Base Rate Loans, quarterly on the last business day of each of March, June, September and December. An unused commitment fee is also payable with respect to the revolving credit facility and the delayed draw term loan facility ranging between 0.35 % and 0.50 % depending on the Company’s first lien net leverage ratio, and is payable quarterly in arrears with respect to the revolving credit facility and on the earliest of the termination of the delayed draw term loan facility, the six month anniversary of the Closing Date with respect to any delayed draw term loan commitments that have expired and otherwise after the end of the first full fiscal quarter after the Closing Date. Amortization payments with respect to the Initial Term Loans are payable in quarterly installments, commencing with the last business day of the first full fiscal quarter ending after the Closing Date, in aggregate principal amounts equal to (i) 1.25 % of the aggregate principal amount of the Initial Term Loans outstanding on the Closing Date from the Closing Date until June 7, 2024, (ii) 1.875 % of the aggregate principal amount of the Initial Term Loans outstanding on the Closing Date from June 8, 2024 to June 7, 2025 and (iii) 2.50 % of the aggregate principal amount of the Initial Term Loans outstanding on the Closing Date from June 8, 2025 to June 7, 2026. All amounts owed under the Credit Facilities are due and payable upon the five-year anniversary of the Closing Date, unless otherwise extended in accordance with the terms of the Credit Agreement. The Credit Agreement contains certain covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness or liens, to make certain investments, to enter into sale-leaseback transactions, to make certain restricted payments, including dividends, to enter into consolidations, mergers or sales of material assets and other fundamental changes, or to transact with affiliates subject to exceptions, materiality and other qualifications as provided in the Credit Agreement. The Credit Agreement also contains customary events of default and also includes an equity cure right. All obligations under the Credit Agreement are guaranteed by the Company and substantially all of its subsidiaries. As of December 31, 2021, the Company was in compliance, in all material respects, with all covenants under the First Amendment of the Credit Agreement. On December 30, 2021, the Company entered into the First Amendment to the Credit Agreement to, among other things, modify certain of the financial covenants contained in the Credit Agreement. As of December 31, 2021, the Company was in compliance, in all material respects, with all covenants under the First Amendment of the Credit Agreement. CMG Loan Agreement On the Closing Date, the Company repaid all outstanding term loan borrowings under CMG's previous loan agreement (the “Loan Agreement”) and the Loan Agreement was terminated. The Company repaid $ 24.5 million, inclusive of $ 487,000 in prepayment penalties, fees and interest. The Company recorded a loss on early of extinguishment of debt of $ 806,000 , inclusive of the write-off of deferred debt issuance costs and prepayment penalties related to the Loan Agreement. Earnout Consideration Other Debt Other long-term debt repaid on the Closing Date totaled $ 229,000 . In addition, $ 2.0 million was deposited into an escrow account as security for amounts borrowed under the Paycheck Protection Program ("PPP"). In the twelve months ended December 31, 2021 , the Company paid $ 2.0 million to the CMG Sellers for the amount owed related to a loan under the PPP. This amount was held in escrow and was reported in restricted cash in the June 30, 2021 condensed consolidated balance sheet, but was released upon forgiveness of the PPP loans. During the twelve months ended December 31, 2021 , borrowings under the PPP of $ 2.8 million were forgiven and are included in the gain on extinguishment of debt. Future Maturities Future maturities of debt outstanding at December 31, 2021 are as follows ( in thousands ): Amount 2022 $ 6,275 2023 6,265 2024 8,611 2025 11,726 2026 89,063 Total $ 121,940

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Stockholders' Equity	NOTE 8. STOCKHOLDERS’ EQUITY The consolidated statement of changes in equity reflects the Reverse Recapitalization and the IMC Acquisition as discussed in Notes 2 and 3. As CMG was deemed the accounting acquirer in the Reverse Recapitalization with DFHT, all periods prior to the consummation of the Business Combination reflect the balances and activity of CMG. In connection with the Business Combination, the Company adopted the third amended and restated certificate of incorporation, dated June 8, 2021 (the “Amended and Restated Charter”) to, among other things, increase the total number of authorized shares of all classes of capital stock, par value of $ 0.0001 per share, to 261,000,000 shares, consisting of (i) 260,000,000 shares of common stock, including 250,000,000 shares of Class A Common Stock and 10,000,000 shares of Class B Common Stock, and (ii) 1,000,000 shares of preferred stock. In addition, 3,593,750 shares of Class B Common Stock were converted, on a one -for-one basis, into shares of Class A Common Stock , and as of December 31, 2021 , there were no shares of Class B Common Stock issued or outstanding. Also in connection with the Business Combination, (i) Deerfield Partners and the Sponsor purchased an aggregate of 10,000,000 shares of Class A Common Stock (the “Deerfield PIPE Investments”), consisting of 9,600,000 shares of Class A Common Stock purchased by Deerfield Partners and 400,000 shares of Class A Common Stock purchased by the Sponsor, for a purchase price of $ 10.00 per share and an aggregate purchase price of $ 100.0 million and (ii) certain investors purchased an aggregate of 31,000,000 shares of Class A Common Stock (the “Third-Party PIPE Investments,” and together with the Deerfield PIPE Investments, the “PIPE Investments”), for a purchase price of $ 10.00 per share, for an aggregate purchase price of $ 310.0 million. The Company paid offering costs of $ 12.8 million. In connection with the acquisition of SMA (see Note 3 – Acquisitions - Acquisition of SMA Entities), the Company issued 384,615 shares of Class A Common Stock. On July 13, 2021, the Company issued 500,000 shares of Class A Common Stock in connection with the execution of the Advisory Agreement (as defined below). In connection with the DNF Acquisition (see Note 3 – Acquisitions - Acquisition of DNF), the Company issued 2,741,528 shares of Class A Common Stock to DNF. Also, during the twelve months ended December 31, 2021 , the first tranche of contingently issuable shares totaling an aggregate of 3,200,000 shares of Class A Common Stock were issued to the CMG Sellers and IMC Parent (“Earnout Shares” described in Contingent Consideration below). On December 22, 2021, the Company issued 145,883 shares of Class A Common Stock in connection with the acquisition of Advantis (see Note 3 - Acquisitions - Acquisition of Advantis). On December 22, 2021, the Company issued 148,104 shares of Class A Common Stock in connection with the acquisition of BIX (see Note 3 - Acquisitions - Acquisition of BIX). Related Advisory Agreement On July 13, 2021, the Company entered into an exclusive real estate advisory agreement (the "Advisory Agreement") with Related CM Advisor, LLC (the “Advisor”), a Delaware limited liability company and a subsidiary of The Related Companies, L.P. (“Related”) (the “Advisory Agreement”), pursuant to which the Advisor has agreed provide certain real estate advisory services to the Company on an exclusive basis. The services include identifying locations for new medical centers nationwide as part of the Company’s de novo growth strategy, including, but not limited to, locations within and proximate to affordable housing communities that may be owned by Related. In connection with the Advisory Agreement, the Company and the Advisor entered into a subscription agreement (the “Subscription Agreement”), whereby the Advisor purchased 500,000 shares (the “Initial Shares”) of the Company’s Class A Common Stock for an aggregate purchase price of $ 5.0 million and the Company issued to the Advisor (i) a warrant (the “Series A Warrant”) to purchase 2,000,000 shares of Class A Common Stock (the “Series A Warrant Shares”), which vested immediately upon issuance, is exercisable for a period of five years and is not redeemable by the Company and (ii) a warrant (the “Series B Warrant” and together with the Series A Warrant, the “Warrants”) to purchase up to 6,000,000 shares of Class A Common Stock (the “Series B Warrant Shares” and, together with the Series A Warrant Shares, the “Warrant Shares”), pursuant to which 500,000 Series B Warrant Shares will vest and become exercisable from time to time upon the opening of each medical center under the Advisory Agreement for which the Advisor provides services, other than two initial medical centers. The Series B Warrant is exercisable, to the extent vested, until the later of five years from the date of issuance or one year from vesting of the applicable Series B Warrant Shares and is redeemable with respect to vested Warrant Shares at a price of $ 0.01 per Warrant Share if the price of the Class A Common Stock equals or exceeds $ 18.00 per share, or $ 0.10 per Warrant Share if the price of the Class A Common Stock equals or exceeds $ 10.00 per share, in each case when such price conditions are satisfied for any 20 trading days within a 30-trading day period and subject to certain adjustments and conditions as described in the Series B Warrant. In the event that the Series B Warrant is called for redemption by the Company, the Advisor may pay the exercise price for the Series B Warrant Shares six months following the notice of redemption by the Company. The company assessed the substance of the Subscription Agreement and determined that all instruments referenced in the Subscription Agreement should be assessed under the guidance of ASC 718 as non-employee awards issued to Related in exchange for real estate advisory services to be rendered per the Advisory Agreement. As a result, the Company recorded the Series A Warrants as a component of additional paid-in-capital using the fair value as of July 13, 2021. Preferred Stock The Amended and Restated Charter authorizes the Company to issue 1,000,000 shares of preferred stock, with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of December 31, 2021 , there were no shares of preferred stock issued or outstanding. Redeemable Warrants - Public Warrants On July 16, 2020, in connection with the IPO, DFHT sold 2,875,000 Public Warrants. Each whole Public Warrant entitles the registered holder to purchase one share of Class A Common Stock at a price of $ 11.50 per share, subject to adjustment, at any time commencing on the later of 12 months from the closing of the IPO and 30 days after the completion of the Business Combination , provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of Class A Common Stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their Public Warrants on a cashless basis under the circumstances specified in the warrant agreement) and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Pursuant to the warrant agreements entered into at the time of the IPO, a warrant holder may exercise its Public Warrants only for a whole number of shares of Class A Common Stock. This means only a whole Public Warrant may be exercised at a given time by a warrant holder. No fractional warrants were issued upon separation of the units issued in connection with the IPO and only whole Public Warrants will trade. The Company may redeem the Public Warrants when the price per share of Class A Common Stock equals or exceeds certain threshold prices. Redeemable Warrants - Private Placement Warrants Also in connection with the IPO, DFHT issued the 2,916,667 Private Placement Warrants at a purchase price of $ 1.50 per warrant. The Private Placement Warrants (including the Class A Common Stock issuable upon exercise of the Private Placement Warrants) are not transferable, assignable or salable until 30 days after the completion of the Business Combination (except, among other limited exceptions to DFHT’s officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants) and they will not be redeemable by CareMax for cash so long as they are held by the initial stockholders or their permitted transferees. With some exceptions, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants. If the Private Placement Warrants are held by holders other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. Contingent Consideration Pursuant to the Business Combination Agreement, the CMG Sellers and IMC Parent, who received Class A Common Stock in connection with the Business Combination, became entitled to receive Contingent Consideration to be paid out in the form of Class A Common Stock. The Business Combination Agreement provided that u p to an additional 3,500,000 and 2,900,000 Earnout Shares would become payable after the Closing to the CMG sellers and IMC Parent, respectively: (i) if within the first year after the Closing, the volume weighted average trading price of Class A Common Stock equals or exceeds $ 12.50 on any 20 trading days in any 30-day trading period (the “First Share Price Trigger”), then 1,750,000 and 1,450,000 Earnout Shares would become issuable to the CMG Sellers and IMC Parent, respectively, and (ii) if within the two years after the Closing (the “Second Earnout Period”), the volume weighted average trading price of Class A Common Stock equals or exceeds $ 15.00 on any 20 trading days in any 30-day trading period (the “Second Share Price Trigger” and together with the First Share Price Trigger, the “Share Price Triggers”), then 1,750,000 and 1,450,000 Earnout Shares would become issued and paid to the formers owners of CMG and IMC, respectively. If prior to (i) the satisfaction of the Share Price Triggers, and (ii) the end of the Second Earnout Period, the Company enters into a change in control transaction as described in the Business Combination Agreement, and the price per share of the Company’s Class A Common Stock payable to the stockholders of the Company in such change in control transaction is greater than the Share Price Triggers that have not been satisfied during the Earnout Period, then at closing of such change in control transaction, the Share Price Triggers would be deemed to have been satisfied and the Company shall issue, as of such closing, all of the Earnout Shares. The contingent consideration was classified as a liability for the period ended June 30, 2021. On July 9th, 2021, the volume weighted average trading price of Class A Common Stock exceeded the $ 12.50 on 20 or more days resulting in the satisfaction of the First Share Price Trigger. After the First Share Price Trigger was achieved on July 9, 2021, the estimated fair value of the Earnout Shares was recorded as an equity-classified instrument as a component of stockholders' equity, with the change in fair value from the prior reporting period recorded in earnings. Accordingly, 1,750,000 and 1,450,000 Earnout Shares were issued and paid to the CMG Sellers and IMC Parent, respectively. See Item 9A. – Controls and Procedures - Material Weaknesses in Internal Control over Financial Reporting for further information on the classification of the Earnout Shares. Equity Based Compensation Expense - 2021 Plan On June 4, 2021, the stockholders of the Company approved the CareMax Inc. 2021 Long-term Incentive Plan (the “2021 Plan”), effective on the Closing Date. The 2021 Plan permits the grant of equity-based awards to officers, directors, employees and other service providers. The 2021 Plan permits the grant of an initial share pool of 7,000,000 shares of Class A Common Stock and will: - be increased automatically, without further action of the Company’s board of directors, on January 1st of each calendar year commencing after the Closing Date and ending on (and including) January 1, 2031, by a number of shares of Class A Common Stock equal to the lesser of (i) four percent of the aggregate number of shares of Class A Common Stock outstanding on December 31st of the immediately preceding calendar year, excluding for this purpose any such outstanding shares of Class A Common Stock that were granted under the 2021 Plan and remain unvested and subject to forfeiture as of the relevant December 31st, or (B) a lesser number of shares of Class A Common Stock as determined by the Company’s board of directors or the Compensation Committee of the board of directors prior to the relevant January 1 st . Service and Performance-Based Awards Beginning on October 29, 2021, the Board of Directors approved individual awards under the 2021 Plan. Awards consisted of RSU's for employees, executives, and directors, PSUs for executives, and Options for Executives. For the RSU's granted to employees, the service-based vesting will be satisfied with respect to 33.3 % of an employee's RSU's on October 29, 2022, the first anniversary of the vesting commencement date, and will be satisfied with respect to 33.3 % of an employee's RSU's at the end of each twelve month period thereafter (October 29, 2023 and 2024), subject to the employee's continued employment with the Company through the applicable vesting date. For the RSU's granted to executives, the service-based vesting will be satisfied with respect to 33.3 % of an executive's RSU's on October 29, 2022, the first anniversary of the vesting commencement date, and will be satisfied with respect to 33.3 % of an executive's RSU's on June 8th, 2023, and June 8th, 2024, subject to the executive's continued employment with the Company through the applicable vesting date. For the RSU's granted to directors, the service-based vesting will be satisfied with respect to 100 % of a director's RSU's on October 29, 2022, the first anniversary of the vesting commencement date, subject to the director's continued employment with the Company through the applicable vesting date. For the PSU's issued to executives, the performance-based vesting will be satisfied with respect to a percentage of an employee's PSU's, as and when the price per share of Class A Common Stock specified is achieved, on a volume-adjusted weighted-average basis 30 days prior to July 1, 2023, the expiration of the awards, subject to the executives continued employment with the Company through the applicable vesting date. The Options provide the executive the option to purchase a defined number of shares at a strike price of $ 10.00 . The Options service-based vesting will be satisfied with respect to 33.3 % of an executive's Options on October 29, 2022, the first anniversary of the vesting commencement date, and will be satisfied with respect to 33.3 % of an executive's Options on June 8th, 2023, and June 8th, 2024, subject to the executives continued employment with the Company through the applicable vesting date. The Company accounts for forfeitures as they occur. RSU Valuation The following table summarizes the activity related to the Company's RSUs for the twelve months ended December 31, 2021 (in thousands, except for weighted average grant date fair value):  Number of RSUs Wtd. Avg. Grant Date Fair Value Outstanding as of January 1, 2021 - $ - Granted 975 $ 7.92 Vested - $ - Forfeited - $ - Unvested and outstanding as of December 31, 2021 975 $ 7.92 The total fair value of RSU's that vested during the twelve months ended December 31, 2021 was $ 0 . As of December 31, 2021, total unrecognized compensation expense related to unvested RSU's was $ 7.7 million and is expected to be recognized over a weighted-average expected performance period of 2.6 years. PSU Valuation The following table summarizes the activity related to the Company's PSUs for the twelve months ended December 31, 2021 (in thousands, except for weighted average grant date fair value):  Number of PSUs Wtd. Avg. Grant Date Fair Value Outstanding as of January 1, 2021 - $ - Granted 66 $ 6.05 Vested - $ - Forfeited - $ - Unvested and outstanding as of December 31, 2021 66 $ 6.05 The total fair value of PSU's that vested during the twelve months ended December 31, 2021 was $ 0 . As of December 31, 2021, total unrecognized compensation expense related to unvested PSU's was $ 397,000 and is expected to be recognized over a weighted-average expected performance period of 1.7 years. The fair-value of the PSU's with market-based vesting conditions was determined on the date of grant using a Monte Carlo model to simulate total stockholder return for the Company and peer companies with the following assumptions: Performance Period 1.7 Weighted-Average risk-free interest rate 0.37 % Weighted-average volatility 55.0 % Weighted-average dividend yield 0.0 % The risk-free interest rate utilized is based on a 10 -year term-matched zero-coupon U.S. Treasury security yield at the time of grant. Expected volatility is based on annualized standard deviation of daily continuously compounded returns of the Company's peer firms using the Guideline Public Companies method. Option Valuation The following table summarizes the activity related to the Company's Options for the twelve months ended December 31, 2021 (in thousands, except for weighted average grant date fair value):  Number of Options Wtd. Avg. Grant Date Fair Value Outstanding as of January 1, 2021 - $ - Granted 131 $ 5.82 Vested - $ - Forfeited - $ - Unvested and outstanding as of December 31, 2021 131 $ 5.82 The total fair value of Options that vested during the twelve months ended December 31, 2021 was $ 0 . As of December 31, 2021, total unrecognized compensation expense related to unvested Options' was $ 764,000 and is expected to be recognized over a weighted-average expected performance period of 2.6 years. The fair-value of the Options with market-based vesting conditions was determined on the date of grant using a Black-Scholes-Merton Option Pricing model to simulate total stockholder return for the Company and peer companies with the following assumptions: Performance Period 0.8 Weighted-Average risk-free interest rate 1.55 % Weighted-average volatility 54.7 % Weighted-average dividend yield 0.0 % The risk-free interest rate utilized is based on an interpolated term-matched zero-coupon U.S. Treasury security yield at the time of grant. Expected volatility is based on annualized standard deviation of daily continuously compounded returns of the Company's peer firms using the Guideline Public Companies method. In accordance with ASC 718 - Compensation - Stock Compensation, the awards were classified as equity and the Company began recognizing share based compensation expense based on the grant date fair value. Share-based compensation expense is included within Corporate, General and Administrative expenses in the consolidated statements of operations. The company recognized share-based compensation expense as follows (in thousands):  December 31, 2021 December 31, 2020 RSU's $ 290 $ - PSU's 41 - Options 44 - Class A Common Stock 966 - Total share-based compensation expense $ 1,341 $ - As of December 31, 2021 , no awards have vested and there were no shares of Class A Common Stock issued or outstanding under the 2021 Plan. In July 2021, the Company’s board of directors authorized an award of 100,000 shares of Class A Common Stock to an executive. The award has not been granted as of December 31, 2021 . There are no additional performance or market conditions that will be required to be satisfied before the award is granted. Due to the timing of communicating the terms of the award to the executive, the Company used September 30, 2021 for the grant date fair value. The historical close price of the Class A Common Stock was $ 9.66 on September 30, 2021. As of December 31, 2021 , the Class A Common Stock shares have no t been issued for this award. The Company has recorded Equity Based Compensation expense totaling $ 1.3 million for the twelve months ended December 31, 2021 .

Net Income (Loss) Per Share

Net Income (Loss) Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	NOTE 9. NET INCOME (LOSS) PER SHARE The Business Combination was accounted for as a reverse recapitalization by which CMG issued equity for the net assets of the Company accompanied by a recapitalization. Earnings per share has been recast for all historical periods to reflect the Company’s capital structure for all comparative periods. The Earnout Shares are excluded from the computation of basic net income (loss) per share until the conditions to trigger the issuance of the Earnout Shares have been satisfied. During the twelve months ended December 31, 2021 , the first tranche of Earnout Shares totaling 3,200,000 shares of Class A Common Stock were issued to the CMG Sellers and IMC Parent, and such shares are included in the computation of basic net income (loss) per share from the date of issuance for the twelve months ended December 31, 2021 . The remaining Earnout Shares totaling 3,200,000 shares were excluded from the computation of basic net income (loss) per share for the twelve months ended December 31, 2021 as the conditions to trigger the issuance of the Earnout Shares had not been satisfied as of December 31, 2021. The Company excluded the effect of the Public Warrants and the Private Placement Warrants from the computation of diluted net income (loss) per share in the twelve months ended December 31, 2021 as their inclusion would have been anti-dilutive because the Company was in a loss position for the period. The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common share outstanding for the period subsequent to the transactions that occurred in connection with the Business Combination ( in thousands, except share and per share data ): Twelve Months Ended December 31, 2021 2020 Net (loss) income attributable to CareMax, Inc. Class A common $ ( 6,675 ) $ 7,601 Weighted average basic shares outstanding 52,620,980 10,796,069 Weighted average diluted shares outstanding 52,620,980 10,796,069 Net (loss) income per share Basic $ ( 0.13 ) $ 0.70 Diluted $ ( 0.13 ) $ 0.70

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 10. FAIR VALUE MEASUREMENTS The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value ( in thousands ). December 31, 2021 Quoted Prices Significant other Significant other Description (Level 1) (Level 2) (Level 3) Derivative warrant liabilities $ — $ — $ 8,375 Liability-classified contingent consideration — — 875 The fair value of the Public Warrants issued in connection with the IPO and the Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model and subsequently, the fair value of the Private Placement Warrants has been estimated using a Monte Carlo simulation model each measurement date. The fair value of Public Warrants issued in connection with the IPO has been measured based on the listed market price of such warrants since the IPO. For the twelve months ended December 31, 2021 , the Company recognized a benefit resulting from a decrease in the fair value of the derivative warrant liabilitie s of $ 20.8 million. Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period. There were no transfers between levels for twelve months ended December 31, 2021. The estimated fair value of the Private Placement Warrants, and the Public Warrants prior to being separately listed and traded, was determined using Level 3 inputs. Inherent in a Monte Carlo simulation are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock based on historical volatility of select peer companies that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The following table provides quantitative information regarding Level 3 fair value measurements inputs as of the Closing (June 8, 2021) and December 31, 2021: December 31, June 8, Exercise price $ 11.50 $ 11.50 Unit price $ 7.68 $ 14.92 Volatility 37.6 % 29.8 % Expected life of the options to convert 4.44 5 Risk-free rate 1.17 % 0.77 % Dividend yield 0.0 % 0.0 % The change in the fair value of the warrant liabilities for the twelve months ended December 31, 2021 is summarized as follows ( in thousands ): Fair value of derivative warrant liabilities at Closing $ 29,132 Change in fair value of derivative warrant liabilities ( 20,757 ) Derivative warrant liabilities at December 31, 2021 $ 8,375 The following table provides quantitative information regarding Level 3 fair value measurements of the Related Warrants as of the date of issuance: July 13, Exercise price $ 11.50 Unit price $ 13.30 Volatility 50.9 % Expected life of the options to convert 5.00 Risk-free rate 0.85 % Dividend yield 0.0 % The following table provides quantitative information regarding Level 3 fair value measurements of both tranches of the Contingent Consideration for the CMG Sellers and IMC Parent as of the date in which the First Share Price was triggered, causing the instruments to be re-assessed under ASWC 815-40 and subsequent reclassification from liabilities to equity: CMG Sellers - First Share Price Trigger July 9, Share Price Trigger $ 12.50 Potential Shares 1,750,000 Beginning Share Price $ 14.09 Volatility 60.7 % Remaining Term 0.92 Risk-free rate 0.22 % Dividend yield 0.0 % CMG Sellers - Second Share Price Trigger July 9, Share Price Trigger $ 15.00 Potential Shares 1,750,000 Beginning Share Price $ 14.09 Volatility 60.7 % Remaining Term 1.92 Risk-free rate 0.22 % Dividend yield 0.0 % IMC Parent - First Share Price Trigger July 9, Share Price Trigger $ 12.50 Potential Shares 1,450,000 Beginning Share Price $ 14.09 Volatility 60.7 % Remaining Term 0.92 Risk-free rate 0.22 % Dividend yield 0.0 % IMC Parent - Second Share Price Trigger July 9, Share Price Trigger $ 15.00 Potential Shares 1,450,000 Beginning Share Price $ 14.09 Volatility 60.7 % Remaining Term 1.92 Risk-free rate 0.22 % Dividend yield 0.0 %

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 11. RELATED PARTY TRANSACTIONS The Company had a 49 % ownership interest in Care Smile, LLC (“Care Smile”), a dental care organization with majority ownership by the dental provider, who is the spouse of a member of the Company's senior management. The Company pays for dental services provided to enrollees by Care Smile on a capitated basis. Total capitation payments for the twelve months ended December 31, 2020 were $ 222,000 . The net loss of Care Smile for the twelve months ended December 31, 2020 was $ 97,000 . Care Smile was voluntarily dissolved on November 24, 2020. The Company leases certain facilities from related parties under operating leases expiring through 2036 . Rent expenses totaled $ 21,000 for the twelve months ended December 31, 2021. On July 13, 2021, the Company entered into the Advisory Agreement the Advisor, the substance of which is described in detail in Note 8 - Stockholders Equity – Related Advisory Agreement. The relative fair value method was used to allocate the $ 5.0 million purchase price between the shares of Class A Common Stock and the Series A Warrants under the Subscription Agreement. The Company recorded the excess of the grant date fair value difference between the fair value of the equity and Series A Warrants instruments at the grant date (July 13, 2021) as prepaid service contracts totaling $ 14.5 million, subject to amortization over the terms of the respective agreements. In the twelve months ended December 31, 2021, the Company recognized $ 215,000 of expense related to amortization of the prepaid service contracts. The Series B Warrants were assigned a value of $ 0 as the vesting was not probable at issuance through the twelve months ended December 31, 2021. The grant date fair value of the Series B Warrants will be used to determine the cost of these awards upon the opening of the 12 future sites not yet identified. On July 13, 2021 the Company's board of directors appointed Mr. Bryan Cho, an Executive Vice President of Related, to serve as a Class III director of the Company. The appointment of Mr. Cho was made in connection with the Advisory Agreement, which provides the Advisor with the right to designate a director to serve on the Company's board of directors, subject to the continuing satisfaction of certain conditions, including that the Advisor and its affiliates maintain ownership of at least 500,000 shares of Class A Common Stock. The board of directors has determined that Mr. Cho is independent under the rules of the Nasdaq Stock Market, LLC. Mr. Cho has been appointed to serve as a member on the Compensation Committee and Nominating and Governance Committee of the Board. As a director of the Company, Mr. Cho will receive compensation in the same manner as the Company’s other non-employee directors and will enter into the Company’s standard indemnification agreement for directors.

Operating Leases and Commitment

Operating Leases and Commitments	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Operating Leases and Commitments	NOTE 12. OPERATING LEASES AND COMMITMENTS The Company has entered into non-cancelable operating lease agreements for office and clinical space expiring at various times through 2031 . The operating lease agreements have renewal options ranging from one to seven years . Future minimum rental payments under these lease agreements, including renewal options which are considered reasonably certain of exercise, consisted of the following at December 31, 2021: Amount 2022 $ 10,087 2023 10,028 2024 9,715 2025 9,374 2026 8,685 Thereafter 58,763 Total $ 106,652 Rent expense, including other related expenses for property taxes, sale taxes, and utilities, was approximately $ 7.2 million for the twelve months ended December 31, 2021 and $ 1.5 million for the twelve months ended December 31, 2020 , respectively. Rent expense is included in Corporate General and Administrative Expenses in the consolidated statements of operations

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 13. INCOME TAXES Prior to the Business Combination on June 8, 2021, CMG was taxed as a partnership for income tax purposes whereby the owners were subject to and liable for the income taxes on earnings of the company. No income tax expense or deferred taxes were recorded by CMG for a prior period and as such no comparable prior year amounts are disclosed. As a result of the current year Business Combination, the tax status of CMG was changed from a partnership to a C Corporation. The components of income tax expense (benefit) from continuing operations for the twelve months ended December 31, 2021 are as follows (in thousands): December 31, 2021 Deferred: Federal $ 126 State 33 (Decrease) Increase in valuation allowance - Total income tax expense $ 159 The reconciliation between the effective tax rate and the statutory tax rate is as follows: December 31, 2021 Federal statutory rate 21.0 % State statutory rate, net of federal benefit 4.9 % Nondeductible Transaction Costs ( 14.2 %) Nondeductible/nontaxable or other items ( 0.2 %) PPP Loan Forgiveness 8.1 % Change in valuation allowance ( 22.1 %) Income tax (expense) ( 2.5 %) Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The primary temporary differences that give rise to the deferred tax assets and liabilities are depreciation and amortization, interest expense, and net operating loss carryforwards. The deferred tax assets and liabilities consisted of the following at December 31, 2021 (in thousands): December 31, 2021 Deferred tax assets: Accrued Expenses $ 2,257 Warrant Liabilities 2,219 Loss carryforwards 15,982 Interest carryforward 6,962 Other - Total deferred tax assets 27,420 Valuation allowance ( 26,128 ) Net deferred tax assets 1,292 Deferred tax liabilities: Intangibles ( 1,480 ) Property, plant and equipment ( 18 ) Prepaid Expenses ( 219 ) Other - Total deferred tax liabilities ( 1,717 ) Deferred tax liabilities, net $ ( 425 ) The deferred tax assets were fully offset by a valuation allowance at December 31, 2021 , except for a portion attributable to a “naked credit” deferred tax liability. As of December 31, 2021 we had federal and state tax loss carryforwards of $ 60.2 million and $ 60.9 million, respectively. Federal net operating losses of $ 9.0 million generated prior to December 31, 2017 will expire in 2037 if not utilized. Federal net operating losses generated after January 1, 2018 will have an indefinite carryforward period. We anticipate approximately $ 43.9 million in losses and $ 21.9 million of business expense limitation carried over from the Business Combination with IMC on June 8, 2021 will be subject to potential Section 382 limitations. Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2021. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth. We have indefinitely-lived intangible assets consisting of goodwill. Pursuant to FASB ASC 350-10, these indefinitely-lived intangible assets are not amortized for financial reporting purposes. However, these assets are tax deductible, and therefore amortized over 15 years for tax purposes. As such, deferred income tax expense and a deferred tax liability arise as a result of the tax-deductibility of these indefinitely-lived intangible assets. The resulting deferred tax liability, which is expected to continue to increase over time, will have an indefinite life, resulting in what is referred to as a “naked credit.” This deferred tax liability could remain on our balance sheet indefinitely unless there is an impairment of the related assets (for financial reporting purposes), or the business to which those assets relate were to be disposed of. Due to the fact that the aforementioned deferred tax liability could have an indefinite life, it can only be netted against the portion of our other indefinitely lived deferred tax assets (which primarily relate to post-2018 net operating loss and business interest expense carryforwards) when determining the required valuation allowance. Doing so would result in the understatement of the valuation allowance and related deferred income tax expense. As a result, a full valuation has been recorded against the Company's net deferred tax assets, except for this excess deferred tax liability (“naked credit”). We are subject to taxation in the United States and Florida. As of December 31, 2021 , all tax years from 2017 remain open to examination by the major taxing jurisdictions to which we are subject due to our net operating loss and credit carryforwards from those years. We believe that the income tax filing positions will be sustained on audit and do not anticipate any adjustments that will result in a material change. Therefore, no reserve for uncertain income tax positions has been recorded. Interest and penalties, if any, associated with income tax examinations will be to record such items as a component of income taxes.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 14. COMMITMENTS AND CONTINGENCIES Compliance The health care industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statues and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with imposition of significant fines and penalties, as well as significant repayments for patient services billed. Compliance with these laws and regulations, specifically those related to the Medicare and Medicaid programs, can be subject to government review and interpretation, as well as regulatory actions unknown and not yet asserted at this time. Management believes that the Company is in substantial compliance with current laws and regulations. Malpractice Professional Liability Insurance The Company may be a party to claims filed against it in the normal course of business, principally related to malpractice assertions. The Company has professional liability insurance coverage on a claims-made basis. Current per claim coverage is limited to $ 1.0 million and aggregate annual claims of $ 3.0 million. Should this claims-made policy not be renewed or replaced with equivalent insurance, claims based on incidents occurring during the term of the claims-made policy but reported in subsequent periods would be uninsured. The Company has determined that no accrual is necessary for incurred but not reported (“IBNR”) claims as of December 31, 2021 and 2020. The Company has secured coverage through May 2022, and intends to renew coverage beyond this date. Litigation The Company is involved in various legal actions arising in the normal course of business. Management has not identified any legal actions during the fiscal year ended December 31, 2021 that were deemed to be material.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	NOTE 15. SUBSEQUENT EVENTS The Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K, and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements include the account of CareMax Inc. and its wholly owned subsidiaries (collectively "CareMax" or "the Company"). Intercompany accounts and transactions have been eliminated. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for annual financial information and in accordance with the instructions to Form 10-K/A and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). In the opinion of management, the accompanying consolidated financial statements include all adjustments of a normal recurring nature, which are necessary for a fair presentation of financial position, operating results and cash flows for the periods presented. Pursuant to the Business Combination, the acquisition of CMG by DFHT was accounted for as a reverse recapitalization in accordance with GAAP (the “Reverse Recapitalization”). Under this method of accounting, DFHT was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of CMG issuing equity for the net assets of DFHT, accompanied by a recapitalization. The net assets of DFHT are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of CMG. Further, CMG was determined to be the accounting acquirer in the acquisition of IMC (the “IMC Acquisition”), as such, the acquisition is considered a business combination under Accounting Standards Codification ("ASC") Topic 805, " Business Combinations ," and was accounted for using the acquisition method of accounting. CareMax recorded the fair value of assets acquired and liabilities assumed from IMC.The presented financial information for the twelve months ended December 31, 2021 includes the financial information and activities for (i) IMC for the period from June 8, 2021 to (and including) December 31, 2021 (206 days), (ii) SMA (as defined in Note 3 - Acquisitions) for the period from June 18, 2021 to (and including) December 31, 2021 (196 days) and (iii) DNF (as defined in Note 3 - Acquisitions) for the period from September 1, 2021 to (and including) December 31, 2021 (121 days). Unless otherwise noted, information for periods prior to the Closing of Business Combination reflects the financial information of CMG only. The consolidated financial statements include the accounts and operations of the Company. All intercompany accounts and transactions have been eliminated.
Restatement of Previously Reported Financial Statements	Restatement of Previously Reported Financial Statements In conjunction with the Company's close process for the year ended December 31, 2022, management identified an error related to classification of equity consideration issued to the Company's real estate advisor in July 2021 (the "Prepaid Asset"). The Prepaid Asset was previously presented as part of the Company's short-term assets, in prepaid expenses. The Company determined that because the Prepaid Asset relates to services that are performed by the real estate advisor over multiple years, the Prepaid Asset should be recorded in other assets, except for the portion that represents the Prepaid Asset amortization expense expected to be recognized during the next twelve months following a given period. The following table reflects the impact of the restatement to the specified line items presented in the Company's previously reported consolidated balance sheet as of December 31, 2021: (in thousands) As Previously Reported Adjustment As Restated ASSETS Affected financial statement line items Prepaid expenses 17,040 ( 13,254 ) 3,786 Total Current Assets $ 108,044 $ ( 13,254 ) $ 94,790 Other assets 2,706 13,254 15,960 There was no impact on the condensed consolidated statement of operations, statements of changes in stockholders'/members' equity or statement of cash flows. The accompanying applicable Notes have been updated to reflect the restatement described above.
Segment Financial Information	Segment Financial Information The Company’s chief operating decision maker regularly reviews financial operating results on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company identifies operating segments based on this review by its chief operating decision maker and operates in and reports as a single operating segment, which is to care for its patients’ needs. For the periods presented, all of the Company’s long-lived assets were located in the United States, and all revenue was earned in the United States.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The areas where significant estimates are used in the accompanying financial statements include, but are not limited to, purchase price allocations, including fair value estimates of intangibles and contingent consideration; the valuation of and related impairment recognitions of long-lived assets; the valuation of the derivative warrant liabilities; the estimated useful lives of fixed assets and intangible assets, including internally developed software; settlements related to revenue and the revenue accrual and accrued expenses. Actual results could differ from those estimates.
Emerging Growth Company	Emerging Growth Company Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to nonemerging growth companies, but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Additionally, as an emerging growth company, the Company is exempt from the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, and the Company’s independent registered public accounting firm is not required to evaluate and report on the effectiveness of internal control over financial reporting.
Acquisitions	Acquisitions The Company accounts for business combinations under the acquisition method of accounting, in accordance with ASC Topic 805, Business Combinations , which requires assets acquired and liabilities assumed to be recognized at their fair values on the acquisition date. Any excess of the fair value of purchase consideration over the fair value of the assets acquired less liabilities assumed is recorded as goodwill. The fair values of the assets acquired, and liabilities assumed are determined based upon the valuation of the acquired business and involves management making significant estimates and assumptions.
Revenue Recognition	Revenue Recognition Since capitated revenue is received regardless of whether services are performed, the performance obligation is the completion of enrollment of the patient and providing access to care. Fee-for-service revenue generally relates to contracts with patients in which our performance obligation is to provide healthcare services to the patients. Revenues are recorded during the period our obligations to provide healthcare services are satisfied. Medicare Risk-based and Medicaid Risk-based revenue consists primarily of capitated fees for medical services provided by us under capitated arrangements directly made with various Medicare Advantage and Medicaid managed care payors. The Company receives a fixed fee per patient under what is typically known as a “risk contract.” Risk contracting, or full risk capitation, refers to a model in which the Company receives from the third-party payor a fixed payment of At-risk premium less an administrative charge for reporting on enrollees on a per patient per month basis (“PPPM” payment) for a defined patient population, and the Company is then responsible for providing healthcare services required by that patient population. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers. The Company’s payor contracts generally have a term of one year or longer, but the contracts between the enrolled members (our customers) and the payor are one calendar year or less. In general, the Company considers all contracts with customers (enrolled members) as a single performance obligation to stand ready to provide managed healthcare services. The Company identified that contracts with customers for capitation arrangements have similar performance obligations and therefore groups them into one portfolio. This performance obligation is satisfied as the Company stands ready to fulfill its obligation to enrolled members. Settlements with third-party payors for retroactive adjustments due to capitation risk adjustment, or claim audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the following factors: • Geography of the service location • Demographics of members • Health needs of members • Method of reimbursement (capitation or fee for service) • Enrollment changes • Rate changes; and • For fee for service activities, the payors (for example, Medicare, Medicaid, commercial insurance, patient) which have different reimbursement/payment methodologies. The Company has elected the practical expedient allowed under ASC 606-10-32-18, “Revenue from Contracts with Customers-The Existence of a Significant Financing Component in the Contract,” and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Company’s expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. The Company has applied the practical expedient provided by ASC 340-40-25-4, “Other Assets and Deferred Costs,” and all incremental customer contract acquisition costs are expensed as they are incurred as the amortization period of the asset that the Company otherwise would have recognized is one year or less in duration. For the twelve months ended December 31, 2021 and 2020, substantially all of the revenue recognized by the Company was from goods and services, namely, providing access to physicians and wellness centers. Other Revenue Other revenue includes professional capitation payments. These revenues are a fixed amount of money per patient per month paid in advance for the delivery of primary care services only, whereby the Company is not liable for medical costs in excess of the fixed payment. Capitated revenues are typically prepaid monthly to the Company based on the number of patients selecting us as their primary care provider. Our capitated rates are fixed, contractual rates. Incentive payments for Healthcare Effectiveness Data and Information Set (“HEDIS”) and any services paid on a fee for service basis by a health plan are also included in other revenue. Other revenue also includes ancillary fees earned under contracts with certain payors for the provision of certain care coordination and other care management services. These services are provided to patients covered by these payors regardless of whether those patients receive their care from our affiliated medical groups. Revenue for primary care service for patients in a partial risk or up-side only contracts are reported in other revenue.
Concentration of Credit Risk and Significant Customers	Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and accounts receivable. The Company’s cash balances with individual banking institutions are in excess of federally insured limits from time to time. The Company believes it is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash and cash equivalents. Anthem, Inc. ("Anthem") represented approximately 27 % and 100 % of the Company’s accounts receivable balance as of December 31, 2021 and December 31, 2020, respectively. Anthem represented 35 % and 93 % of the Company’s revenues for the three months ended December 31, 2021 and 2020 and 48 % and 96 % of the Company’s revenues for the twelve months ended December 31, 2021 and 2020 , respectively.
Accounts Receivable	Accounts Receivable Accounts receivable are carried at the amounts the Company deems collectible. Accordingly, an allowance is provided based on credit losses expected over the contractual term. Accounts receivable are written off when they are deemed uncollectible. As of December 31, 2021 and 2020, the Company believes no allowance is necessary.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: Level 1 - defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets. Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Derivative Instruments	Derivative Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants and contingent consideration, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 “Distinguishing Liabilities from Equity,” and ASC 815-15, “Derivatives and Hedging - Embedded Derivatives. ” The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company issued 2,875,000 common stock warrants in connection with DFHT's initial public offering (the “IPO”) (the “Public Warrants”). Simultaneously with the closing of the IPO, DFHT consummated the private placement of 2,916,667 common stock warrants (the “Private Placement Warrants”). The Public Warrants and Private Placement Warrants are accounted for as derivative warrant liabilities in accordance with ASC 815-40, “ Derivatives and Hedging - Contracts in an Entity's Own Equity .” Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s consolidated statement of operations. The fair value of the Public Warrants and Private Placement Warrants was initially measured at fair value using a Monte Carlo simulation model and subsequently, the fair value of the Private Placement Warrants has been estimated using a Monte Carlo simulation model at each measurement date. The fair value of Public Warrants issued in connection with the IPO has subsequently been measured based on the listed market price of such warrants. In connection with the Business Combination, up to 6,400,000 shares of Class A Common Stock become issuable under certain circumstances to IMC Parent and the CMF Sellers as contingent consideration (the “Contingent Consideration”). The Contingent Consideration was accounted for as derivative warrant liabilities in accordance with ASC 815-40, “ Derivatives and Hedging - Contracts in an Entity's Own Equity .” Accordingly, the Company recognized the Contingent Consideration as liabilities at fair value in the second quarter of 2021 following a restatement of the Company’s unaudited condensed consolidated financial statements for the periods ended June 30, 2021 and September 30, 2021 (see Note – Stockholders Equity – Contingent Consideration for further information). The liabilities were subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s consolidated statement of operations. On July 9, 2021, the First Share Price Trigger (as defined below) was achieved, and the remaining Contingent Consideration was re-assessed and determined to be indexed to the Company's own equity, resulting in equity classification under ASC 815-40 “ Derivatives and Hedging - Contracts in an Entity's Own Equity .” The remaining Contingent Consideration was recorded at fair value on July 9, 2021, the date of the event that caused the reclassification. Changes in the fair value upon reclassification from liability to equity were recorded in earnings. See Note 8 – Stockholders Equity – Contingent Consideration for further information.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill represents the excess of consideration transferred in excess of the fair value of net assets acquired through business acquisitions. Pursuant to ASC 350, “Intangibles – Goodwill and Other,” we review goodwill annually in the fourth quarter or whenever significant events or changes indicate the possibility of impairment. For purposes of the annual goodwill impairment assessment, the Company has identified a single reporting unit. The most recently completed impairment test of goodwill was performed in the fourth quarter of 2021, and it was determined that the fair value of goodwill was in excess of the carrying value, therefore no impairment was necessary. Intangible assets with a finite useful life are amortized over their useful lives. We review the recoverability of any long-lived intangible assets whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable.
Impairment of Long-lived Assets	Impairment of Long-lived Assets Long-lived assets, such as equipment, improvements, and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the use and eventual disposition of the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value.
Property and Equipment	Property and Equipment Property and equipment is recorded at cost. Maintenance and repairs are charged to expense as incurred. Depreciation is provided over the estimated useful life of each class of depreciable asset and is computed on the straight-line method. Leasehold improvements are depreciated over the lesser of the length of the related lease plus any renewal options or the estimated life of the asset. A summary of estimated useful lives is as follows: Leasehold Improvements 15 to 39 Years Furniture and Equipment 5 to 7 Years Vehicles 5 Years Software 3 Years
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “ Income Taxes .” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2021 and December 31, 2020 . The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.
External Provider Costs	External Provider Costs External Provider Costs include capitation payments and fee for service claims paid, claims in process and pending, and an estimate of unreported claims and charges by physicians, hospitals, and other health care providers for services rendered to enrollees during the period. Changes to prior-period estimates of medical expenses are reflected in the current period.
Share-Based Compensation Expense	Share-Based Compensation Expense The Company periodically issues Restricted Stock Units ("RSU's"), Performance Share Units ("PSUs"), and Stock Options ("Options") as share-based compensation to employees and non-employees in non-capital raising transactions for services. The Company accounts for such grants issued and vesting based on FASB ASC 718, Compensation – Stock Compensation (Topic 718), whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered. The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting Measurement of share-based payment transactions with non-employees are recognized as compensation expense in the financial statements based on their fair values at grant date. That expense is recognized over the period during which a non-employees or consultant is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The fair value of the Company’s Options, RSUs and PSUs are estimated using the Black-Scholes-Merton Option Pricing model and a Monte Carlo simulation, respectively, which use certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or stock, and future dividends. Compensation expense for Options , RSUs and PSUs are recorded based upon the values derived from the Black-Scholes-Merton Option Pricing model and the Monte Carlo simulation, respectively. The assumptions used in the Black-Scholes-Merton Option Pricing model and Monte Carlo Simulation(s) could materially affect compensation expense recorded in future periods. The assumptions used in the model and related impact are discussed in Note 8 - Stockholders Equity .
Net Income (Loss) Per Share	Net Income (Loss) Per Share Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. The Company follows the provisions of ASC Topic 260, Earnings Per Share , for determining whether contingently issuable shares are included for purposes of calculating net income (loss) per share and determining whether instruments granted in equity-based compensation arrangements are participating securities for purposes of calculating net income (loss) per share. See Note 9 - Net Income (Loss) Per Share.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, " Leases " (“ASU 2016-02”), which amended the accounting for leases, requiring lessees to recognize most leases on their balance sheet with a right-of-use asset and a lease liability. Leases will be classified as either finance or operating leases, which will impact the expense recognition of such leases over the lease term. ASU 2016-02 also modifies the lease classification criteria for lessors and eliminates some of the real estate leasing guidance previously applied for certain leasing transactions. In June 2020, the FASB issued ASU 2020-05, “ Revenue from Contracts with Customers and Leases ,” that deferred the required effective date for non-issuers to fiscal years beginning after December 15, 2021 and to interim periods within fiscal years beginning after December 15, 2022. The Company adopted ASU 2016-02 on January 1, 2022. Because of the number of leases the Company utilizes to support its operations, the adoption of ASU 2016-02 is expected to have a significant impact on the Company’s financial position and results of operations. The total future estimated gross annual lease payments are $ 106.7 million as of December 31, 2021 . We expect this standard to increase our total assets and total liabilities by approximately 12 % percent. We do not expect the standard to have a material impact on our results of operations. In preparation for the adoption of the standard, we have procured a third-party software to track and manage our leases, loaded lease data into the software, authored our accounting policy, trained our business units on the new standard and policy and the use of the software, and modified our control environment accordingly. We have not experienced significant issues in our implementation process. In June 2016, the FASB issued ASU 2016-13, " Financial Instruments – Credit Losses (Topic 326) : Measurement of Credit Losses on Financial Instruments" (“ASU 2016-13”). ASU 2016-13 introduced a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The guidance became effective for us beginning January 1, 2022. The new current expected credit losses model generally calls for the immediate recognition of all expected credit losses and applies to loans, accounts and trade receivables as well as other financial assets measured at amortized cost, loan commitments and off-balance sheet credit exposures, debt securities and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The new guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available for sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. The Company adopted this standard on January 1, 2022 and does not believe adoption will have a material effect on its consolidated financial statements. In January 2020, the FASB issued ASU 2020-01, " Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323) , and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815" (“ASU 2020-01”). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact the adoption of ASU 2020-01 will have on its consolidated financial statements. In March 2020, the FASB issued guidance to provide temporary optional expedients and exceptions through December 31, 2022 to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing Rate (SOFR). The amendments are effective for all entities from the beginning of an interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The Company is currently evaluating the effect the update will have on its consolidated financial statements and related disclosures. In October 2021, the FASB issued ASU 2021-08, "Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." The ASU improves comparability after business combinations by providing consistent recognition and measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not acquired in a business combination. ASU 2021-08 is effective for the Company on January 1, 2023, with early adoption permitted. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements. We do not expect that any other recently issued accounting guidance will have a significant effect on our consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Estimated Useful Lives of Property and Equipment	A summary of estimated useful lives is as follows: Leasehold Improvements 15 to 39 Years Furniture and Equipment 5 to 7 Years Vehicles 5 Years Software 3 Years
Schedule of Impact of Restatement to Specified Line Items in Unaudited Condensed Consolidated Balance Sheet	The following table reflects the impact of the restatement to the specified line items presented in the Company's previously reported consolidated balance sheet as of December 31, 2021: (in thousands) As Previously Reported Adjustment As Restated ASSETS Affected financial statement line items Prepaid expenses 17,040 ( 13,254 ) 3,786 Total Current Assets $ 108,044 $ ( 13,254 ) $ 94,790 Other assets 2,706 13,254 15,960

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2021
IMC
Business Acquisition [Line Items]
Summary of Purchase Consideration	The purchase consideration was comprised of the following (in thousands): Cash consideration (1) $ 172,302 Share consideration (2) $ 155,347 Contingent consideration (3) $ 40,785 Other consideration (4) $ 1,271 (1) Represents cash consideration inclusive of the payment of $ 79.8 million of IMC debt simultaneous with the Closing and the reimbursement of IMC Parent's transaction costs of $ 7.3 million. (2) Represent the issuance of 10,412,023 shares of Class A Common Stock, which shares were issued at a reference price of $ 10.00 per share, but the value of which was $ 14.92 per share, the closing price on the date of the IMC Acquisition. (3) Represents the fair value of equity-classified contingent consideration. (4) Represents the fair value of cash and equity purchase consideration held in escrow pending the finalization of final closing adjustments.
Summary of Purchase Consideration and Preliminary Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the purchase consideration and the preliminary fair value of the assets acquired and liabilities assumed ( in thousands ):  Purchase price allocation Cash $ 14,842 Accounts receivable 21,298 Other current assets 1,446 Property, plant, & equipment 6,198 Intangible assets 34,121 Other assets 448 Accounts payable and accrued expenses ( 8,793 ) Long term debt ( 197 ) Other long term liabilities ( 1,898 ) Net Assets Acquired 67,465 Excess of Consideration over Net Assets Acquired 302,240 Total Consideration $ 369,705
SMA Entities
Business Acquisition [Line Items]
Summary of Purchase Consideration	The purchase consideration was comprised of the following ( in thousands ): Cash consideration (1) $ 52,000 Share consideration (2) $ 5,027 (1) Represents cash consideration of $ 52.0 million inclusive of $ 2.5 million held in escrow and $ 145,000 in SMA seller transaction cost. (2) Represents equity consideration of 384,615 shares of Class A Common Stock valued at $ 5.0 million based on the June 18, 2021 closing price of $ 13.07 .
Summary of Purchase Consideration and Preliminary Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the consideration paid and the preliminary fair value of the assets acquired and liabilities assumed ( in thousand s):  Purchase price allocation Cash $ 73 Accounts receivable 1,830 Property, plant, & equipment 178 Intangible assets 9,404 Other assets 29 Accounts payable and accrued expenses ( 178 ) Net Assets Acquired 11,336 Excess of Consideration over Net Assets Acquired 45,691 Total Consideration $ 57,027
DNF
Business Acquisition [Line Items]
Summary of Purchase Consideration	The purchase consideration was comprised of the following ( in thousands ): Cash consideration (1) $ 88,118 Share consideration (2) $ 26,072 (1) Represents cash consideration of $ 88.1 million inclusive of $ 11.0 million held in escrow and $ 242,000 in DNF seller transaction costs. (2) Represents equity consideration of 2,741,528 shares of Class A Common Stock valued at $ 26.1 million based on the September 1, 2021 closing price of $ 9.51 .
Summary of Purchase Consideration and Preliminary Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the purchase consideration and the preliminary fair value of the assets acquired ( in thousands ):  Purchase price allocation Accounts receivable $ 3,732 Property, plant, & equipment 3,520 Intangible assets 15,329 Other assets 65 Net Assets Acquired 22,646 Excess of Consideration over Net Assets Acquired 91,544 Total Consideration $ 114,190
Advantis
Business Acquisition [Line Items]
Summary of Purchase Consideration	The purchase consideration was comprised of the following ( in thousands ): Cash consideration (1) $ 9,865 Share consideration (2) $ 1,107 (1) Represents cash consideration of $ 9.9 million inclusive of $ 900,000 held in escrow and $ 60,000 in Advantis seller transaction cost (2) Represents equity consideration of 145,883 shares of Class A Common Stock valued at $ 1.1 million based on the December 22, 2021 closing price of $ 7.59 .
Summary of Purchase Consideration and Preliminary Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the purchase consideration and the preliminary fair value of the assets acquired ( in thousands) :  Purchase price allocation Accounts receivable $ 242 Property, plant, & equipment 18 Intangible assets 1,064 Other assets 20 Net Assets Acquired 1,344 Excess of Consideration over Net Assets Acquired 9,628 Total Consideration $ 10,972
Business Intelligence & Analytics LLC
Business Acquisition [Line Items]
Summary of Purchase Consideration	The purchase consideration was comprised of the following ( in thousands ): Cash consideration (1) $ 4,000 Share consideration (2) $ 1,124 (1) Represents cash consideration of $ 4.0 million. (2) Represents equity consideration of 148,104 shares of Class A Common Stock valued at $ 1.1 million based on the December 22, 2021 closing price of $ 7.59 .
Summary of Purchase Consideration and Preliminary Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the purchase consideration and the preliminary fair value of the assets acquired ( in thousands) :  Purchase price allocation Intangible assets 289 Net Assets Acquired 289 Excess of Consideration over Net Assets Acquired 4,835 Total Consideration $ 5,124

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Changes in Carrying Amount of Goodwill	The following table shows changes in the carrying amount of goodwill from December 31, 2020 to December 31, 2021 ( in thousands ): Carrying Amount Balance at December 31, 2020 $ 10,068 Acquired goodwill during the period 454,498 Balance at December 31, 2021 $ 464,566
Summary of Gross Carrying Amount and Accumulated Amortization of Intangible Assets by Major Class	The following table summarizes the gross carrying amounts and accumulated amortization of intangible assets by major class ( in thousands ): Gross Carrying Accumulated Net Book Weighted Average December 31, 2021 Risk Contracts $ 64,822 $ ( 9,818 ) $ 55,004 7 Non-compete agreements 4,202 ( 686 ) 3,516 5 Trademarks 1,867 ( 827 ) 1,040 2 Patents/Developed Technology 235 - 235 5 In-Process Research and Development 16 - 16 1 Total $ 71,141 $ ( 11,331 ) $ 59,811 Gross Carrying Accumulated Net Book Weighted Average December 31, 2020 Risk Contracts $ 8,174 $ ( 682 ) $ 7,492 11 Non-compete agreements 1,320 ( 237 ) 1,083 5 Total $ 9,494 $ ( 919 ) $ 8,575
Schedule of Estimated Amortization Expense Related to Fair Value of Acquired Intangible Assets	The estimated amortization expense related to the fair value of acquired intangible assets for each of the succeeding five years and thereafter is ( in thousands ): 2022 $ 15,134 2023 12,234 2024 10,199 2025 8,547 2026 7,616 Thereafter 6,082

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	A summary of property and equipment at December 31, 2021 and December 31, 2020 is as follows ( in thousands ): December 31, 2021 December 31, 2020 Leasehold improvements $ 7,516 $ 2,726 Vehicles 3,711 2,823 Furniture and equipment 5,470 1,983 Software 2,950 - Construction in progress 2,254 360 Total 21,902 7,892 Less: Accumulated depreciation ( 5,909 ) ( 3,096 ) Total Property and equipment, net $ 15,993 $ 4,796

Long Term Debt (Tables)

Long Term Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Summary of Long-Term Debt	Long-term debt consisted of the following at December 31, 2021 and December 31, 2020 ( in thousands ): December 31, December 31, Secured term loans $ 121,875 $ 24,184 Payroll protection plan - 2,164 Other 65 1,358 Unamortized debt issuance costs ( 4,704 ) ( 377 ) 117,236 27,329 Current portion ( 6,275 ) ( 1,004 ) Long-term portion $ 110,960 $ 26,325
Summary of Future Maturities of Debt Outstanding	Future maturities of debt outstanding at December 31, 2021 are as follows ( in thousands ): Amount 2022 $ 6,275 2023 6,265 2024 8,611 2025 11,726 2026 89,063 Total $ 121,940

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Summary of RSUs Activity	The following table summarizes the activity related to the Company's RSUs for the twelve months ended December 31, 2021 (in thousands, except for weighted average grant date fair value):  Number of RSUs Wtd. Avg. Grant Date Fair Value Outstanding as of January 1, 2021 - $ - Granted 975 $ 7.92 Vested - $ - Forfeited - $ - Unvested and outstanding as of December 31, 2021 975 $ 7.92
Summary of PSUs Activity	The following table summarizes the activity related to the Company's PSUs for the twelve months ended December 31, 2021 (in thousands, except for weighted average grant date fair value):  Number of PSUs Wtd. Avg. Grant Date Fair Value Outstanding as of January 1, 2021 - $ - Granted 66 $ 6.05 Vested - $ - Forfeited - $ - Unvested and outstanding as of December 31, 2021 66 $ 6.05
Assumptions Used to Calculate Fair Value of PSUs	The fair-value of the PSU's with market-based vesting conditions was determined on the date of grant using a Monte Carlo model to simulate total stockholder return for the Company and peer companies with the following assumptions: Performance Period 1.7 Weighted-Average risk-free interest rate 0.37 % Weighted-average volatility 55.0 % Weighted-average dividend yield 0.0 %
Summary of Options Activity	The following table summarizes the activity related to the Company's Options for the twelve months ended December 31, 2021 (in thousands, except for weighted average grant date fair value):  Number of Options Wtd. Avg. Grant Date Fair Value Outstanding as of January 1, 2021 - $ - Granted 131 $ 5.82 Vested - $ - Forfeited - $ - Unvested and outstanding as of December 31, 2021 131 $ 5.82
Assumptions Used to Calculate Fair Value of Options	The fair-value of the Options with market-based vesting conditions was determined on the date of grant using a Black-Scholes-Merton Option Pricing model to simulate total stockholder return for the Company and peer companies with the following assumptions: Performance Period 0.8 Weighted-Average risk-free interest rate 1.55 % Weighted-average volatility 54.7 % Weighted-average dividend yield 0.0 %
Schedule of Share-based Compensation Expense Recognized	The company recognized share-based compensation expense as follows (in thousands):  December 31, 2021 December 31, 2020 RSU's $ 290 $ - PSU's 41 - Options 44 - Class A Common Stock 966 - Total share-based compensation expense $ 1,341 $ -

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Summary of Calculation of Basic and Diluted Earnings Per Share	The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common share outstanding for the period subsequent to the transactions that occurred in connection with the Business Combination ( in thousands, except share and per share data ): Twelve Months Ended December 31, 2021 2020 Net (loss) income attributable to CareMax, Inc. Class A common $ ( 6,675 ) $ 7,601 Weighted average basic shares outstanding 52,620,980 10,796,069 Weighted average diluted shares outstanding 52,620,980 10,796,069 Net (loss) income per share Basic $ ( 0.13 ) $ 0.70 Diluted $ ( 0.13 ) $ 0.70

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value ( in thousands ). December 31, 2021 Quoted Prices Significant other Significant other Description (Level 1) (Level 2) (Level 3) Derivative warrant liabilities $ — $ — $ 8,375 Liability-classified contingent consideration — — 875
Schedule of Quantitative Information of Level 3 Fair Value Measurements Inputs	The following table provides quantitative information regarding Level 3 fair value measurements inputs as of the Closing (June 8, 2021) and December 31, 2021: December 31, June 8, Exercise price $ 11.50 $ 11.50 Unit price $ 7.68 $ 14.92 Volatility 37.6 % 29.8 % Expected life of the options to convert 4.44 5 Risk-free rate 1.17 % 0.77 % Dividend yield 0.0 % 0.0 % The following table provides quantitative information regarding Level 3 fair value measurements of the Related Warrants as of the date of issuance: July 13, Exercise price $ 11.50 Unit price $ 13.30 Volatility 50.9 % Expected life of the options to convert 5.00 Risk-free rate 0.85 % Dividend yield 0.0 % The following table provides quantitative information regarding Level 3 fair value measurements of both tranches of the Contingent Consideration for the CMG Sellers and IMC Parent as of the date in which the First Share Price was triggered, causing the instruments to be re-assessed under ASWC 815-40 and subsequent reclassification from liabilities to equity: CMG Sellers - First Share Price Trigger July 9, Share Price Trigger $ 12.50 Potential Shares 1,750,000 Beginning Share Price $ 14.09 Volatility 60.7 % Remaining Term 0.92 Risk-free rate 0.22 % Dividend yield 0.0 % CMG Sellers - Second Share Price Trigger July 9, Share Price Trigger $ 15.00 Potential Shares 1,750,000 Beginning Share Price $ 14.09 Volatility 60.7 % Remaining Term 1.92 Risk-free rate 0.22 % Dividend yield 0.0 % IMC Parent - First Share Price Trigger July 9, Share Price Trigger $ 12.50 Potential Shares 1,450,000 Beginning Share Price $ 14.09 Volatility 60.7 % Remaining Term 0.92 Risk-free rate 0.22 % Dividend yield 0.0 % IMC Parent - Second Share Price Trigger July 9, Share Price Trigger $ 15.00 Potential Shares 1,450,000 Beginning Share Price $ 14.09 Volatility 60.7 % Remaining Term 1.92 Risk-free rate 0.22 % Dividend yield 0.0 %
Schedule of Change in Fair Value of Warrant Liabilities	The change in the fair value of the warrant liabilities for the twelve months ended December 31, 2021 is summarized as follows ( in thousands ): Fair value of derivative warrant liabilities at Closing $ 29,132 Change in fair value of derivative warrant liabilities ( 20,757 ) Derivative warrant liabilities at December 31, 2021 $ 8,375

Operating Leases and Commitme_2

Operating Leases and Commitments (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of Future Minimum Rental Payments	Future minimum rental payments under these lease agreements, including renewal options which are considered reasonably certain of exercise, consisted of the following at December 31, 2021: Amount 2022 $ 10,087 2023 10,028 2024 9,715 2025 9,374 2026 8,685 Thereafter 58,763 Total $ 106,652

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Components of Income Tax Expense (Benefit) from Continuing Operations	The components of income tax expense (benefit) from continuing operations for the twelve months ended December 31, 2021 are as follows (in thousands): December 31, 2021 Deferred: Federal $ 126 State 33 (Decrease) Increase in valuation allowance - Total income tax expense $ 159
Summary of Reconciliation Between Effective Tax Rate	The reconciliation between the effective tax rate and the statutory tax rate is as follows: December 31, 2021 Federal statutory rate 21.0 % State statutory rate, net of federal benefit 4.9 % Nondeductible Transaction Costs ( 14.2 %) Nondeductible/nontaxable or other items ( 0.2 %) PPP Loan Forgiveness 8.1 % Change in valuation allowance ( 22.1 %) Income tax (expense) ( 2.5 %)
Summary of Deferred Tax Assets and Liabilities	The deferred tax assets and liabilities consisted of the following at December 31, 2021 (in thousands): December 31, 2021 Deferred tax assets: Accrued Expenses $ 2,257 Warrant Liabilities 2,219 Loss carryforwards 15,982 Interest carryforward 6,962 Other - Total deferred tax assets 27,420 Valuation allowance ( 26,128 ) Net deferred tax assets 1,292 Deferred tax liabilities: Intangibles ( 1,480 ) Property, plant and equipment ( 18 ) Prepaid Expenses ( 219 ) Other - Total deferred tax liabilities ( 1,717 ) Deferred tax liabilities, net $ ( 425 )

Description of Business - Addit

Description of Business - Additional Information (Details)			12 Months Ended
	Jul. 13, 2021 shares	Jun. 08, 2021 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) Center $ / shares shares	Dec. 31, 2020 USD ($)
Description Of Business [Line Items]
Cash consideration | $			$ 309,707,000	$ 2,566,000
Number of wholly owned operating multi-specialty medical centers | Center			45
Class A Common Stock
Description Of Business [Line Items]
Proceeds from the sale of Class A common stock, net of offering costs (in shares)	500,000
Common stock, par value | $ / shares			$ 0.0001
Conversion basis			In addition, 3,593,750 shares of Class B Common Stock were converted, on a one-for-one basis, into shares of Class A Common Stock
Common stock, shares issued			87,367,972
Common stock, shares outstanding			87,367,972
Class A Common Stock | Business Combination Agreement
Description Of Business [Line Items]
Proceeds from the sale of Class A common stock, net of offering costs (in shares)		10,000,000
Class B Common Stock
Description Of Business [Line Items]
Common stock, shares issued			0
Common stock, shares outstanding			0
Private Placement | Class A Common Stock | Business Combination Agreement
Description Of Business [Line Items]
Common stock, par value | $ / shares		$ 0.0001
Conversion basis			all of the 3,593,750 issued and outstanding shares of Class B common stock of the Company, par value $0.0001 per share (“Class B Common Stock”), automatically converted, on a one-for-one basis, into shares of Class A Common Stock
Common stock, shares issued			3,593,750
Common stock, shares outstanding			3,593,750
Private Placement | Class B Common Stock | Business Combination Agreement
Description Of Business [Line Items]
Common stock, par value | $ / shares		$ 0.0001
CMG | Business Combination Agreement
Description Of Business [Line Items]
Percentage of equity interests acquired		100%
Cash consideration | $		$ 364,000,000
Purchase consideration, net | $		$ 229,400,000
Business combination purchase consideration percentage		68%
Adjustment escrow amounts | $		$ 500,000
Adjustment escrow amounts in cash | $		$ 340,000
Adjustment escrow amounts in shares (as a percent)		68%
CMG | Class A Common Stock | Business Combination Agreement
Description Of Business [Line Items]
Reference price (in dollars per share) | $ / shares		$ 10
Authorized earnout shares (in shares)		3,500,000
Adjustment escrow amounts in shares		16,000
Adjustment escrow amounts in shares (as a percent)		32%
CMG | Private Placement | Class A Common Stock | Business Combination Agreement
Description Of Business [Line Items]
Proceeds from the sale of Class A common stock, net of offering costs (in shares)		10,796,069
IMC
Description Of Business [Line Items]
Percentage of equity interests acquired		100%
Cash consideration | $		$ 172,302,000
Purchase consideration, net | $		$ 369,700,000
Reference price (in dollars per share) | $ / shares		$ 10
IMC | Business Combination Agreement
Description Of Business [Line Items]
Percentage of equity interests acquired		100%
IMC | Class A Common Stock
Description Of Business [Line Items]
Reference price (in dollars per share) | $ / shares		$ 14.92
IMC Parent | Business Combination Agreement
Description Of Business [Line Items]
Cash consideration | $		$ 250,000,000
Purchase consideration, net | $		$ 85,200,000
Business combination purchase consideration percentage		45%
Adjustment escrow amounts | $		$ 1,000,000
Adjustment escrow amounts in cash | $		$ 450,000
Adjustment escrow amounts in shares (as a percent)		45%
IMC Parent | Class A Common Stock | Business Combination Agreement
Description Of Business [Line Items]
Reference price (in dollars per share) | $ / shares		$ 10
Authorized earnout shares (in shares)		2,900,000
Adjustment escrow amounts in shares		55,000
Adjustment escrow amounts in shares (as a percent)		55%
IMC Parent | Private Placement | Class A Common Stock | Business Combination Agreement
Description Of Business [Line Items]
Proceeds from the sale of Class A common stock, net of offering costs (in shares)		10,412,023

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		12 Months Ended
	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2021 USD ($) Portfolio shares	Dec. 31, 2020 USD ($)
Summary of Significant Accounting Policies [Line Items]
Goodwill	$ 464,566,000	$ 10,068,000	$ 464,566,000	$ 10,068,000
Number of portfolio | Portfolio			1
Revenue practical expedient financing component [true false]			true
Revenue practical Expedient incremental cost of obtaining contract [true false]			true
Goodwill impairment loss			$ 0
Unrecognized Tax Benefits	0	$ 0	0	$ 0
Total future estimated gross annual lease payments	$ 106,652,000		$ 106,652,000
ASU 2016-02
Summary of Significant Accounting Policies [Line Items]
Percentage of increase in total assets and total liabilities	12%		12%
DFHT
Summary of Significant Accounting Policies [Line Items]
Goodwill	$ 0		$ 0
Other intangible assets	$ 0		$ 0
Public Warrants
Summary of Significant Accounting Policies [Line Items]
Number of warrants issued | shares			2,875,000
Private Placement Warrants
Summary of Significant Accounting Policies [Line Items]
Number of warrants issued | shares			2,916,667
Class A Common Stock
Summary of Significant Accounting Policies [Line Items]
Contingently issuable shares to CareMax and IMC sellers | shares			3,200,000
Class A Common Stock | IMC Parent and CareMax Sellers
Summary of Significant Accounting Policies [Line Items]
Business combination, contingent consideration, number of shares issued | shares			6,400,000
Anthem | Credit Concentration Risk | Accounts Receivable
Summary of Significant Accounting Policies [Line Items]
Concentration risk (as a percentage)			27%	100%
Anthem | Customer Concentration Risk | Revenue
Summary of Significant Accounting Policies [Line Items]
Concentration risk (as a percentage)	35%	93%	48%	96%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Impact of Restatement to Specified Line Items in Unaudited Condensed Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prepaid expenses	$ 3,786	$ 183
Total Current Assets	94,790	14,881
Other assets	15,960	$ 183
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prepaid expenses	17,040
Total Current Assets	108,044
Other assets	2,706
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prepaid expenses	(13,254)
Total Current Assets	(13,254)
Other assets	$ 13,254

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2021
Leasehold Improvements | Minimum
Property Plant And Equipment [Line Items]
Estimated useful lives of property and equipment	15 years
Leasehold Improvements | Maximum
Property Plant And Equipment [Line Items]
Estimated useful lives of property and equipment	39 years
Furniture and Equipment | Minimum
Property Plant And Equipment [Line Items]
Estimated useful lives of property and equipment	5 years
Furniture and Equipment | Maximum
Property Plant And Equipment [Line Items]
Estimated useful lives of property and equipment	7 years
Vehicles
Property Plant And Equipment [Line Items]
Estimated useful lives of property and equipment	5 years
Software
Property Plant And Equipment [Line Items]
Estimated useful lives of property and equipment	3 years

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details)					12 Months Ended
	Dec. 22, 2021 USD ($)	Sep. 01, 2021 USD ($)	Jun. 18, 2021 USD ($)	Jun. 08, 2021 USD ($)	Dec. 31, 2021 USD ($) Business	Dec. 31, 2020 USD ($)
Business Acquisition [Line Items]
Acquisition-related transaction costs					$ 1,522,000	$ 0
Revenue					295,762,000	103,421,000
Net income loss before income taxes					$ (6,516,000)	$ 7,572,000
Risk Contracts
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period					7 years	11 years
Trademarks
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period					2 years
Non-compete Agreements
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period					5 years	5 years
Patents/Developed Technology
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period					5 years
In-Process Research and Development
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period					1 year
IMC
Business Acquisition [Line Items]
Business acquisition, percentage of equity interests acquired				100%
Total purchase consideration				$ 369,700,000
Business acquisition, goodwill recognized , expected to be tax deductible for income tax purposes				80,400,000
Definite-lived intangible assets				$ 34,100,000
Revenue					$ 148,000,000
Net income loss before income taxes					4,100,000
IMC | Minimum
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period				1 year
IMC | Maximum
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period				6 years
IMC | Risk Contracts
Business Acquisition [Line Items]
Definite-lived intangible assets				$ 33,900,000
IMC | Trademarks
Business Acquisition [Line Items]
Definite-lived intangible assets				$ 263,000
SMA Entities
Business Acquisition [Line Items]
Business acquisition, percentage of equity interests acquired			100%
Business acquisition, goodwill recognized , expected to be tax deductible for income tax purposes			$ 45,000,000
Acquisition-related transaction costs			682,000
Definite-lived intangible assets			$ 9,400,000
Revenue					12,000,000
Net income loss before income taxes					564,000
SMA Entities | Minimum
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period			1 year
SMA Entities | Maximum
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period			6 years
SMA Entities | Risk Contracts
Business Acquisition [Line Items]
Definite-lived intangible assets			$ 8,700,000
SMA Entities | Tradenames
Business Acquisition [Line Items]
Definite-lived intangible assets			92,000
SMA Entities | Non-compete Agreements
Business Acquisition [Line Items]
Definite-lived intangible assets			$ 622,000
DNF
Business Acquisition [Line Items]
Business acquisition, percentage of equity interests acquired		100%
Total purchase consideration		$ 114,200,000
Business acquisition, goodwill recognized , expected to be tax deductible for income tax purposes		90,000,000
Acquisition-related transaction costs		1,247,000
Definite-lived intangible assets		$ 15,300,000
Revenue					19,500,000
Net income loss before income taxes					$ (687,000)
DNF | Minimum
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period		1 year
DNF | Maximum
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period		6 years
DNF | Risk Contracts
Business Acquisition [Line Items]
Definite-lived intangible assets		$ 13,200,000
DNF | Trademarks
Business Acquisition [Line Items]
Definite-lived intangible assets		638,000
DNF | Non-compete Agreements
Business Acquisition [Line Items]
Definite-lived intangible assets		$ 1,500,000
Advantis
Business Acquisition [Line Items]
Business acquisition, percentage of equity interests acquired	100%
Total purchase consideration	$ 11,000,000
Business acquisition, goodwill recognized , expected to be tax deductible for income tax purposes	9,600,000
Acquisition-related transaction costs	671,000
Definite-lived intangible assets	$ 1,100,000
Advantis | Minimum
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period	1 year
Advantis | Maximum
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period	6 years
Advantis | Risk Contracts
Business Acquisition [Line Items]
Definite-lived intangible assets	$ 345,000
Advantis | Trademarks
Business Acquisition [Line Items]
Definite-lived intangible assets	176,000
Advantis | Non-compete Agreements
Business Acquisition [Line Items]
Definite-lived intangible assets	$ 544,000
Business Intelligence & Analytics LLC
Business Acquisition [Line Items]
Business acquisition, percentage of equity interests acquired	100%
Total purchase consideration	$ 5,100,000
Business acquisition, goodwill recognized , expected to be tax deductible for income tax purposes	4,800,000
Acquisition-related transaction costs	0
Definite-lived intangible assets	$ 289,000
Business Intelligence & Analytics LLC | Minimum
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period	1 year
Business Intelligence & Analytics LLC | Maximum
Business Acquisition [Line Items]
Definite-lived intangible assets amortized period	5 years
Business Intelligence & Analytics LLC | Trademarks
Business Acquisition [Line Items]
Definite-lived intangible assets	$ 3,000
Business Intelligence & Analytics LLC | Non-compete Agreements
Business Acquisition [Line Items]
Definite-lived intangible assets	35,000
Business Intelligence & Analytics LLC | Patents/Developed Technology
Business Acquisition [Line Items]
Definite-lived intangible assets	235,000
Business Intelligence & Analytics LLC | In-Process Research and Development
Business Acquisition [Line Items]
Indefinite lived intangible asset	$ 16,000
Other Acquisitions
Business Acquisition [Line Items]
Business acquisition, percentage of equity interests acquired					100%
Total purchase consideration					$ 3,700,000
Acquisition-related transaction costs					250,000
Definite-lived intangible assets					$ 1,400,000
Number of additional business acquired | Business					3

Acquisitions - Summary of Purch

Acquisitions - Summary of Purchase Consideration (Details) - USD ($) $ in Thousands					12 Months Ended
	Dec. 22, 2021	Sep. 01, 2021	Jun. 18, 2021	Jun. 08, 2021	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Cash consideration					$ 309,707	$ 2,566
Share consideration					$ 188,678	$ 0
IMC
Business Acquisition [Line Items]
Cash consideration				$ 172,302
Share consideration				155,347
Contingent consideration				40,785
Other consideration				$ 1,271
DNF
Business Acquisition [Line Items]
Cash consideration		$ 88,118
Share consideration		$ 26,072
SMA Entities
Business Acquisition [Line Items]
Cash consideration			$ 52,000
Share consideration			$ 5,027
Advantis
Business Acquisition [Line Items]
Cash consideration	$ 9,865
Share consideration	1,107
Business Intelligence & Analytics LLC
Business Acquisition [Line Items]
Cash consideration	4,000
Share consideration	$ 1,124

Acquisitions - Summary of Pur_2

Acquisitions - Summary of Purchase Consideration (Parenthetical) (Details) - USD ($)	Dec. 22, 2021	Sep. 01, 2021	Jun. 18, 2021	Jun. 08, 2021
IMC
Business Acquisition [Line Items]
Cash consideration inclusive of payment of debt				$ 79,800,000
Business acquisition, seller transaction costs				$ 7,300,000
Business acquisition, share price				$ 10
IMC | Class A Common Stock
Business Acquisition [Line Items]
Business acquisition, equity interest issued number of shares				10,412,023
Business acquisition, share price				$ 14.92
DNF
Business Acquisition [Line Items]
Cash consideration inclusive of payment of debt		$ 88,100,000
Business combination holdback amount		11,000,000
Business acquisition, seller transaction costs		242,000
Business acquisition, equity interest issued value		$ 26,100,000
Business acquisition, share price		$ 9.51
DNF | Class A Common Stock
Business Acquisition [Line Items]
Business acquisition, equity interest issued number of shares		2,741,528
SMA Entities
Business Acquisition [Line Items]
Cash consideration inclusive of payment of debt			$ 52,000,000
Business combination holdback amount			2,500,000
Business acquisition, seller transaction costs			145,000
Business acquisition, equity interest issued value			$ 5,000,000
Business acquisition, share price			$ 13.07
SMA Entities | Class A Common Stock
Business Acquisition [Line Items]
Business acquisition, equity interest issued number of shares			384,615
Advantis
Business Acquisition [Line Items]
Cash consideration inclusive of payment of debt	$ 9,900,000
Business combination holdback amount	900,000
Business acquisition, seller transaction costs	60,000
Business acquisition, equity interest issued value	$ 1,100,000
Business acquisition, share price	$ 7.59
Advantis | Class A Common Stock
Business Acquisition [Line Items]
Business acquisition, equity interest issued number of shares	145,883
Business Intelligence & Analytics LLC
Business Acquisition [Line Items]
Cash consideration inclusive of payment of debt	$ 4,000,000
Business acquisition, equity interest issued value	$ 1,100,000
Business acquisition, share price	$ 7.59
Business Intelligence & Analytics LLC | Class A Common Stock
Business Acquisition [Line Items]
Business acquisition, equity interest issued number of shares	148,104

Acquisitions - Summary of Pur_3

Acquisitions - Summary of Purchase Consideration and Preliminary Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 22, 2021	Sep. 01, 2021	Jun. 18, 2021	Jun. 08, 2021
IMC
Business Acquisition [Line Items]
Cash				$ 14,842
Accounts receivable				21,298
Other current assets				1,446
Property, plant & equipment				6,198
Intangible assets				34,121
Other assets				448
Accounts payable and accrued expenses				(8,793)
Long-term debt				(197)
Other long term liabilities				(1,898)
Net Assets Acquired				67,465
Excess of Consideration over Net Assets Acquired				302,240
Total Consideration				$ 369,705
SMA Entities
Business Acquisition [Line Items]
Cash			$ 73
Accounts receivable			1,830
Property, plant & equipment			178
Intangible assets			9,404
Other assets			29
Accounts payable and accrued expenses			(178)
Net Assets Acquired			11,336
Excess of Consideration over Net Assets Acquired			45,691
Total Consideration			$ 57,027
DNF
Business Acquisition [Line Items]
Accounts receivable		$ 3,732
Property, plant & equipment		3,520
Intangible assets		15,329
Other assets		65
Net Assets Acquired		22,646
Excess of Consideration over Net Assets Acquired		91,544
Total Consideration		$ 114,190
Advantis
Business Acquisition [Line Items]
Accounts receivable	$ 242
Property, plant & equipment	18
Intangible assets	1,064
Other assets	20
Net Assets Acquired	1,344
Excess of Consideration over Net Assets Acquired	9,628
Total Consideration	10,972
Business Intelligence & Analytics LLC
Business Acquisition [Line Items]
Intangible assets	289
Net Assets Acquired	289
Excess of Consideration over Net Assets Acquired	4,835
Total Consideration	$ 5,124

Reinsurance - Additional Inform

Reinsurance - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Effects of Reinsurance [Line Items]
Reinsurance recoveries recognized	$ 14,700,000	$ 11,200,000
Reinsurance premium expense incurred	10,900,000	$ 10,300,000
Maximum
Effects of Reinsurance [Line Items]
Reinsurance stop loss limit per patient per year	200,000
Minimum
Effects of Reinsurance [Line Items]
Reinsurance stop loss limit per patient per year	$ 30,000

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Summary of Changes in Carrying Amount of Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Balance at December 31, 2020	$ 10,068
Acquired goodwill during the period	454,498
Balance at December 31, 2021	$ 464,566

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Gross Carrying Amount and Accumulated Amortization of Intangible Assets by Major Class (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 71,141	$ 9,494
Accumulated Amortization	(11,331)	(919)
Net Book Value	59,811	8,575
Risk Contracts
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	64,822	8,174
Accumulated Amortization	(9,818)	(682)
Net Book Value	$ 55,004	$ 7,492
Weighted Average Amortization Period (years)	7 years	11 years
Non-compete Agreements
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 4,202	$ 1,320
Accumulated Amortization	(686)	(237)
Net Book Value	$ 3,516	$ 1,083
Weighted Average Amortization Period (years)	5 years	5 years
Trademarks
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,867
Accumulated Amortization	(827)
Net Book Value	$ 1,040
Weighted Average Amortization Period (years)	2 years
Patents/Developed Technology
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 235
Net Book Value	$ 235
Weighted Average Amortization Period (years)	5 years
In-Process Research and Development
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 16
Net Book Value	$ 16
Weighted Average Amortization Period (years)	1 year

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 10,400,000	$ 645,000

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Estimated Amortization Expense Related to Fair Value of Acquired Intangible Assets (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2022	$ 15,134
2023	12,234
2024	10,199
2025	8,547
2026	7,616
Thereafter	$ 6,082

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Total Property and equipment, gross	$ 21,902	$ 7,892
Less: Accumulated depreciation	(5,909)	(3,096)
Total Property and equipment, net	15,993	4,796
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total Property and equipment, gross	7,516	2,726
Vehicles
Property Plant And Equipment [Line Items]
Total Property and equipment, gross	3,711	2,823
Furniture and Equipment
Property Plant And Equipment [Line Items]
Total Property and equipment, gross	5,470	1,983
Software
Property Plant And Equipment [Line Items]
Total Property and equipment, gross	2,950	0
Construction in Progress
Property Plant And Equipment [Line Items]
Total Property and equipment, gross	$ 2,254	$ 360

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Estimated Capital expenditures to complete construction in progress	$ 500,000
Depreciation expense	$ 2,813,000	$ 858,000

Long Term Debt - Summary of Lon

Long Term Debt - Summary of Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Long-term debt gross	$ 121,940
Unamortized debt issuance costs	(4,704)	$ (377)
Total long-term debt	117,236	27,329
Current portion	(6,275)	(1,004)
Long-term portion	110,960	26,325
Secured Term Loans
Debt Instrument [Line Items]
Long-term debt gross	121,875	24,184
Payroll Protection Plan
Debt Instrument [Line Items]
Long-term debt gross		2,164
Other
Debt Instrument [Line Items]
Long-term debt gross	$ 65	$ 1,358

Long Term Debt - Additional Inf

Long Term Debt - Additional Information (Details) - USD ($)		12 Months Ended
	Jun. 08, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 08, 2021
Debt Instrument [Line Items]
Debt instrument, interest rate terms		Interest is payable on the outstanding loans under the Credit Facilities based on, at the option of the Company, either: (i) Eurocurrency (with a LIBOR floor of 0.75% per annum) plus variable spreads ranging from 2.75% to 3.50% per annum based on first lien net leverage ratio levels or (ii) the Alternate Base Rate (defined as the highest of (a) the Prime Rate (as defined in the Credit Agreement and established by the Agent), (b) the Federal Funds Rate (as defined in the Credit Agreement) plus 0.50% per annum, and (c) the LIBOR Quoted Rate (as defined in the Credit Agreement) plus 1.00% per annum, in each case, with a floor of 1.75% per annum), plus variable spreads ranging from 1.75% to 2.50% per annum based on first lien net leverage ratio levels. Accrued and unpaid interest is payable with respect to LIBOR loans on the last day of the interest period as selected by the Company but no later than three months, and with respect to Alternate Base Rate Loans, quarterly on the last business day of each of March, June, September and December.
Debt instrument, unused commitment fee terms		An unused commitment fee is also payable with respect to the revolving credit facility and the delayed draw term loan facility ranging between 0.35% and 0.50% depending on the Company’s first lien net leverage ratio, and is payable quarterly in arrears with respect to the revolving credit facility and on the earliest of the termination of the delayed draw term loan facility, the six month anniversary of the Closing Date with respect to any delayed draw term loan commitments that have expired and otherwise after the end of the first full fiscal quarter after the Closing Date.
Gain on extinguishment of debt, net		$ 1,630,000	$ (451,000)
Federal Funds Rate
Debt Instrument [Line Items]
Debt instrument, variable interest rate		0.50%
LIBOR Quoted Rate
Debt Instrument [Line Items]
Debt instrument, outstanding interest rate		1.75%
Debt instrument, variable interest rate		1%
LIBOR Quoted Rate | Eurocurrency
Debt Instrument [Line Items]
Debt instrument, outstanding interest rate		0.75%
Minimum | Eurocurrency
Debt Instrument [Line Items]
Debt instrument, variable interest rate		2.75%
Minimum | LIBOR Quoted Rate
Debt Instrument [Line Items]
Debt instrument, variable interest rate		1.75%
Maximum | Eurocurrency
Debt Instrument [Line Items]
Debt instrument, variable interest rate		3.50%
Maximum | LIBOR Quoted Rate
Debt Instrument [Line Items]
Debt instrument, variable interest rate		2.50%
Initial Term Loans
Debt Instrument [Line Items]
Aggregate principal amount	$ 125,000,000
Debt instrument, percentage of amortization payments of aggregate principal amount to be paid until June 7, 2024		1.25%
Debt instrument, percentage of amortization payments of aggregate principal amount to be paid from June 8, 2024 to June 7, 2025		1.875%
Debt instrument, percentage of amortization payments of aggregate principal amount to be paid from June 8, 2025 to June 7, 2026		2.50%
Debt instrument, due and payable term		5 years
Revolving Credit Facility
Debt Instrument [Line Items]
Aggregate principal amount	40,000,000
Debt instrument, due and payable term		5 years
Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Debt instrument, unused commitment fee percentage		0.35%
Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Debt instrument, unused commitment fee percentage		0.50%
Term Loan Facility
Debt Instrument [Line Items]
Aggregate principal amount	20,000,000
Debt instrument amount drawn				$ 0
Debt instrument, due and payable term		5 years
Term Loan Facility | Minimum
Debt Instrument [Line Items]
Debt instrument, unused commitment fee percentage		0.35%
Term Loan Facility | Maximum
Debt Instrument [Line Items]
Debt instrument, unused commitment fee percentage		0.50%
Paycheck Protection Program
Debt Instrument [Line Items]
Repayments of debt		$ 2,000,000
Gain on extinguishment of debt, net		$ 2,800,000
Escrow Deposit	2,000,000
CMG
Debt Instrument [Line Items]
Repayments of debt	24,500,000
Repayments of penalties, fees and interest	487,000
Gain on extinguishment of debt, net	(806,000)
Other Long-term Debt
Debt Instrument [Line Items]
Repayments of Long-Term Debt	$ 229,000

Long Term Debt - Summary of Fut

Long Term Debt - Summary of Future Maturities of Debt Outstanding (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Debt Disclosure [Abstract]
2022	$ 6,275
2023	6,265
2024	8,611
2025	11,726
2026	89,063
Total	$ 121,940

Stockholders' Equity - Addition

Stockholders' Equity - Additional information (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Jul. 13, 2021	Jun. 08, 2021	Dec. 31, 2021	Dec. 22, 2021	Sep. 01, 2021	Jun. 18, 2021
Class Of Stock [Line Items]
Capital stock, par value		$ 0.0001
Capital stock, shares authorized		261,000,000
Common stock, shares authorized		260,000,000
Preferred stock,authorized		1,000,000	1,000,000
Aggregate purchase price of common shares			$ 6,650
Payment of offering costs			$ 12,800
Preferred stock, issued			0
Preferred stock,outstanding			0
Subscription Agreement | Series A Warrant
Class Of Stock [Line Items]
Number of shares purchased	2,000,000
Exercisable period	5 years
Subscription Agreement | Series A and Series B Warrant
Class Of Stock [Line Items]
Number of shares purchased	6,000,000
Warrant share price	$ 0.10
Subscription Agreement | Series B Warrant
Class Of Stock [Line Items]
Exercisable period	5 years
Number shares vest and exercisable	500,000
Vesting period	1 year
Warrant share price	$ 0.01
Class A Common Stock
Class Of Stock [Line Items]
Common stock, shares authorized		250,000,000	250,000,000
Conversion of Class B to Class A common shares (in shares)		3,593,750
Conversion basis			In addition, 3,593,750 shares of Class B Common Stock were converted, on a one-for-one basis, into shares of Class A Common Stock
Number of Class A common stock issued upon conversion of each share (in shares)		1
Number of shares purchased	500,000
Common stock, shares issued			87,367,972
Common stock, shares outstanding			87,367,972
Contingently issuable shares to CareMax and IMC sellers			3,200,000
Class A Common Stock | Subscription Agreement
Class Of Stock [Line Items]
Number of shares purchased	500,000
Aggregate purchase price of common shares	$ 5,000
Price per share	$ 18
Class A Common Stock | Subscription Agreement | Maximum
Class Of Stock [Line Items]
Price per share	$ 10
Class A Common Stock | Business Combination Agreement
Class Of Stock [Line Items]
Number of shares purchased		10,000,000
Aggregate purchase price of common shares		$ 100,000
Purchase price per share		$ 10
Class A Common Stock | Deerfield Partners | Business Combination Agreement
Class Of Stock [Line Items]
Number of shares purchased		9,600,000
Class A Common Stock | Sponsor | Business Combination Agreement
Class Of Stock [Line Items]
Number of shares purchased		400,000
Class A Common Stock | Investors | Business Combination Agreement
Class Of Stock [Line Items]
Number of shares purchased		31,000,000
Aggregate purchase price of common shares		$ 310,000
Purchase price per share		$ 10
Class A Common Stock | SMA Entities
Class Of Stock [Line Items]
Common stock, shares issued						384,615
Class A Common Stock | DNF
Class Of Stock [Line Items]
Common stock, shares issued					2,741,528
Class A Common Stock | Advantis
Class Of Stock [Line Items]
Common stock, shares issued				145,883
Class A Common Stock | Business Intelligence & Analytics LLC
Class Of Stock [Line Items]
Common stock, shares issued				148,104
Class B Common Stock
Class Of Stock [Line Items]
Common stock, shares authorized		10,000,000
Common stock, shares issued			0
Common stock, shares outstanding			0

Stockholders' Equity - Redeemab

Stockholders' Equity - Redeemable Warrants (Details) - IPO - DFHT - $ / shares		12 Months Ended
	Jul. 16, 2020	Dec. 31, 2021
Public Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants issued	2,875,000
Number of shares issued for each warrant upon conversion	1
Exercise price of warrants	$ 11.50
Warrants exercise period description		any time commencing on the later of 12 months from the closing of the IPO and 30 days after the completion of the Business Combination
Private Placement Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants issued	2,916,667
Issue price of warrant	$ 1.50
Locking period of warrants after completion of business combination	30 days

Stockholders' Equity - Continge

Stockholders' Equity - Contingent Consideration Common Shares (Details) - $ / shares		12 Months Ended
	Jul. 09, 2021	Dec. 31, 2021
First Share Price Trigger
Business Acquisition Contingent Consideration [Line Items]
Minimum weighted average trading price to issue earnout shares	$ 12.50	$ 12.50
Considered trading days for share price trigger	20 days	20 days
Considered trading period for share price trigger		30 days
Second Share Price Trigger
Business Acquisition Contingent Consideration [Line Items]
Minimum weighted average trading price to issue earnout shares		$ 15
Considered trading days for share price trigger		20 days
Considered trading period for share price trigger		30 days
CMG | Maximum
Business Acquisition Contingent Consideration [Line Items]
Earnout shares payable		3,500,000
CMG | First Share Price Trigger
Business Acquisition Contingent Consideration [Line Items]
Earnout shares payable		1,750,000
Earnout shares issued and paid	1,750,000
CMG | Second Share Price Trigger
Business Acquisition Contingent Consideration [Line Items]
Earnout shares payable		1,750,000
IMC | Maximum
Business Acquisition Contingent Consideration [Line Items]
Earnout shares payable		2,900,000
IMC | First Share Price Trigger
Business Acquisition Contingent Consideration [Line Items]
Earnout shares payable		1,450,000
Earnout shares issued and paid	1,450,000
IMC | Second Share Price Trigger
Business Acquisition Contingent Consideration [Line Items]
Earnout shares payable		1,450,000

Stockholders' Equity - Equity-B

Stockholders' Equity - Equity-Based Compensation Expense - 2021 Plan (Details) - $ / shares		12 Months Ended
	Jun. 04, 2021	Dec. 31, 2021
Class A Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued		87,367,972
Common stock, shares outstanding		87,367,972
2021 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity based awards vested during the period		0
2021 Plan | Class A Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Initial shares available under plan	7,000,000
Equity-based compensation incremental description		be increased automatically, without further action of the Company’s board of directors, on January 1st of each calendar year commencing after the Closing Date and ending on (and including) January 1, 2031, by a number of shares of Class A Common Stock equal to the lesser of (i) four percent of the aggregate number of shares of Class A Common Stock outstanding on December 31st of the immediately preceding calendar year, excluding for this purpose any such outstanding shares of Class A Common Stock that were granted under the 2021 Plan and remain unvested and subject to forfeiture as of the relevant December 31st, or (B) a lesser number of shares of Class A Common Stock as determined by the Company’s board of directors or the Compensation Committee of the board of directors prior to the relevant January 1st.
Incremental percentage of shares available for the plan of outstanding shares	4%
Common stock, shares issued		0
Common stock, shares outstanding		0
2021 Plan | Restricted Stock Units ("RSU's") | Award Vesting on October 29, 2022, the first anniversary | Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting rights percentage		33.30%
2021 Plan | Restricted Stock Units ("RSU's") | Award Vesting on October 29, 2022, the first anniversary | Executives
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting rights percentage		33.30%
2021 Plan | Restricted Stock Units ("RSU's") | Award Vesting on October 29, 2022, the first anniversary | Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting rights percentage		100%
2021 Plan | Restricted Stock Units ("RSU's") | Award vesting at end of each twelve month after first anniversary | Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting rights percentage		33.30%
2021 Plan | Restricted Stock Units ("RSU's") | Awards vest each on June 8th 2023, and June 8th, 2024 | Executives
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting rights percentage		33.30%
2021 Plan | Executive Options | Executives
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike price per share		$ 10
2021 Plan | Executive Options | Award Vesting on October 29, 2022, the first anniversary | Executives
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting rights percentage		33.30%
2021 Plan | Executive Options | Awards vest each on June 8th 2023, and June 8th, 2024 | Executives
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting rights percentage		33.30%

Stockholders' Equity - Summary

Stockholders' Equity - Summary of RSUs Activity (Details) - Restricted Stock Units ("RSU's") shares in Thousands	12 Months Ended
	Dec. 31, 2021 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock units, Granted | shares	975
Number of stock units, Ending balance | shares	975
Wtd. Avg. Grant Date Fair Value, Granted | $ / shares	$ 7.92
Wtd. Avg. Grant Date Fair Value, Outstanding, Ending balance | $ / shares	$ 7.92

Stockholders' Equity - RSUs, PS

Stockholders' Equity - RSUs, PSUs and Options (Details)	12 Months Ended
	Dec. 31, 2021 USD ($)
Zero Coupon U.S. Treasury Security
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk free interest rate utilization term based on treasury security yield	10 years
Restricted Stock Units ("RSU's")
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of stock units vested	$ 0
Total unrecognized compensation expense	$ 7,700,000
Total unrecognized compensation expense, weighted-average recognized period	2 years 7 months 6 days
Performance Share Units ("PSUs")
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of stock units vested	$ 0
Total unrecognized compensation expense	$ 397,000
Total unrecognized compensation expense, weighted-average recognized period	1 year 8 months 12 days
Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total unrecognized compensation expense, weighted-average recognized period	2 years 7 months 6 days
Fair value of options vested	$ 0
Total unrecognized compensation expense, options	$ 764,000

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of PSUs Activity (Details) - Performance Share Units ("PSUs") shares in Thousands	12 Months Ended
	Dec. 31, 2021 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock units, Granted | shares	66
Number of stock units, Ending balance | shares	66
Wtd. Avg. Grant Date Fair Value, Granted | $ / shares	$ 6.05
Wtd. Avg. Grant Date Fair Value, Outstanding, Ending balance | $ / shares	$ 6.05

Stockholders' Equity - Assumpti

Stockholders' Equity - Assumptions Used to Calculate Fair Value of PSUs (Details) - Performance Share Units ("PSUs")	12 Months Ended
	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Performance Period	1 year 8 months 12 days
Weighted-Average risk-free interest rate	0.37%
Weighted-average volatility	55%
Weighted-average dividend yield	0%

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Options Activity (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2021 $ / shares shares
Share-Based Payment Arrangement, Disclosure [Abstract]
Number of Options, Granted | shares	131
Number of Options, Outstanding, Ending balance | shares	131
Wtd. Avg. Grant Date Fair Value, Granted | $ / shares	$ 5.82
Wtd. Avg. Grant Date Fair Value, Outstanding, Ending balance | $ / shares	$ 5.82

Stockholders' Equity - Assump_2

Stockholders' Equity - Assumptions Used to Calculate Fair Value of Options (Details) - Options	12 Months Ended
	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Performance Period	9 months 18 days
Weighted-Average risk-free interest rate	1.55%
Weighted-average volatility	54.70%
Weighted-average dividend yield	0%

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Share-based Compensation Expense Recognized (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation expense	$ 1,341
Class A Common Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation expense	966
Restricted Stock Units ("RSU's")
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation expense	290
Performance Share Units ("PSUs")
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation expense	41
Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation expense	$ 44

Stockholders' Equity - Equity B

Stockholders' Equity - Equity Based Compensation Expense Outside of 2021 Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021	Jul. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award granted	0
Equity based Compensation expense	$ 1,341	$ 0
Class A Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity award authorized				100,000
Common stock close price per share			$ 9.66
Shares issued	0

Net Income (Loss) Per Share - A

Net Income (Loss) Per Share - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021 shares
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Remaining earnout shares excluded from computation of basic net income (loss) per share	3,200,000
Class A Common Stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
First tranche of earnout shares issued to CMG Sellers and IMC Parent	3,200,000

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Summary of Calculation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Net (loss) income attributable to CareMax, Inc. Class A common stockholders	$ (6,675)	$ 7,601
Weighted average basic shares outstanding	52,620,980	10,796,069
Weighted average diluted shares outstanding	52,620,980	10,796,069
Net (loss) income per share, Basic	$ (0.13)	$ 0.70
Net (loss) income per share, Diluted	$ (0.13)	$ 0.70

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Financial Liabilities Fair Value
Derivative warrant liabilities	$ 8,375
Recurring Measurement | Level 3
Financial Liabilities Fair Value
Derivative warrant liabilities	8,375
Recurring Measurement | Level 3 | Classified Contingent Consideration
Financial Liabilities Fair Value
Liability	$ 875

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021 USD ($)
Fair Value Disclosures [Abstract]
Recognized benefit resulting from decrease in fair value of derivative warrant liabilities	$ 20,800,000
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Fair Value Adjustment of Warrants
Fair value, liabilities, Level 1 to Level 2 transfers, amount	$ 0
Fair value, liabilities, Level 2 to Level 1 transfers, amount	0
Fair value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0
Fair value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Quantitative Information of Level 3 Fair Value Measurements Inputs (Details) - Level 3				12 Months Ended
	Jul. 13, 2021	Jul. 09, 2021 shares	Jun. 08, 2021	Dec. 31, 2021
Exercise Price
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	11.50		11.50	11.50
Unit Price
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	13.30		14.92	7.68
Share Price Trigger | First Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		12.50
Share Price Trigger | First Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		12.50
Share Price Trigger | Second Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		15
Share Price Trigger | Second Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		15
Potential Shares | First Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, potential shares		1,750,000
Potential Shares | First Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, potential shares		1,450,000
Potential Shares | Second Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, potential shares		1,750,000
Potential Shares | Second Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, potential shares		1,450,000
Beginning Share Price | First Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		14.09
Beginning Share Price | First Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		14.09
Beginning Share Price | Second Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		14.09
Beginning Share Price | Second Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		14.09
Volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	50.9		29.8	37.6
Volatility | First Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		60.7
Volatility | First Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		60.7
Volatility | Second Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		60.7
Volatility | Second Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		60.7
Expected Life of the Options to Convert
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected life of the options to convert	5 years		5 years	4 years 5 months 8 days
Remaining Term | First Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, remaining term		11 months 1 day
Remaining Term | First Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, remaining term		11 months 1 day
Remaining Term | Second Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, remaining term		1 year 11 months 1 day
Remaining Term | Second Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, remaining term		1 year 11 months 1 day
Risk Free Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0.85		0.77	1.17
Risk Free Rate | First Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		0.22
Risk Free Rate | First Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		0.22
Risk Free Rate | Second Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		0.22
Risk Free Rate | Second Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		0.22
Dividend Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0		0	0
Dividend Yield | First Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		0
Dividend Yield | First Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		0
Dividend Yield | Second Share Price Trigger | CMG Sellers
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		0
Dividend Yield | Second Share Price Trigger | IMC Parent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Contingent consideration, measurement input		0

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Change in Fair Value of Warrant Liabilities (Details) - Derivative Warrant Liabilities $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair value of derivative warrant liabilities at Closing	$ 29,132
Change in fair value of derivative warrant liabilities	(20,757)
Derivative warrant liabilities at December 31, 2021	$ 8,375

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)		12 Months Ended
	Jul. 13, 2021	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Net loss		$ (6,675,000)	$ 7,601,000
Operating leases expiring year		2036
Rent expenses		$ 21,000
Series B Warrant
Related Party Transaction [Line Items]
Warrant not probable of vesting at issuance		0
Advisor | Advisory Agreement
Related Party Transaction [Line Items]
Expense related to amortization of prepaid service contract		$ 215,000
Minimum ownership common shares to be maintained by related party	500,000
Advisor | Advisory Agreement | Class A Common Shares and Series A Warrants
Related Party Transaction [Line Items]
Fair value method to allocate purchase price between common shares and warrants	$ 5,000,000
Prepaid service contracts	$ 14,500,000
Care Smile
Related Party Transaction [Line Items]
Ownership interest		49%
Total capitation payments			222,000
Net loss			$ 97,000

Operating Leases and Commitme_3

Operating Leases and Commitments - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lessee Lease Description [Line Items]
Lease expiring term	various times through 2031
Rent expense	$ 7.2	$ 1.5
Maximum
Lessee Lease Description [Line Items]
Operating lease agreements renewal term	7 years
Minimum
Lessee Lease Description [Line Items]
Operating lease agreements renewal term	1 year

Operating Leases and Commitme_4

Operating Leases and Commitments - Schedule of Future Minimum Rental Payments (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Leases [Abstract]
2022	$ 10,087
2023	10,028
2024	9,715
2025	9,374
2026	8,685
Thereafter	58,763
Total	$ 106,652

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Benefit) from Continuing Operations (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Deferred:
Federal	$ 126
State	33
Total income tax expense	$ 159

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation Between Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal statutory rate	21%
State statutory rate, net of federal benefit	4.90%
Nondeductible Transaction Costs	(14.20%)
Nondeductible/nontaxable or other items	(0.20%)
PPP Loan Forgiveness	8.10%
Change in valuation allowance	(22.10%)
Income tax (expense)	(2.50%)

Income Taxes - Summary of Defer

Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Deferred tax assets:
Accrued Expenses	$ 2,257
Warrant Liabilities	2,219
Loss carryforwards	15,982
Interest carryforward	6,962
Total deferred tax assets	27,420
Valuation allowance	(26,128)
Net deferred tax assets	1,292
Deferred tax liabilities:
Intangibles	(1,480)
Property, plant and equipment	(18)
Prepaid Expenses	(219)
Total deferred tax liabilities	(1,717)
Deferred tax liabilities, net	$ (425)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2017	Jun. 08, 2021
Operating Loss Carryforwards [Line Items]
Income tax expense	$ 159,000	$ 0
Operating loss carryforward subject to Section 382 limitation				$ 43,900,000
Operating loss carryforward subject to business expense Section 382 limitation				$ 21,900,000
Goodwill amortization period	15 years
Reserve for unrecognized tax benefits	$ 0
Earliest tax year
Operating Loss Carryforwards [Line Items]
Open tax year	2017
Federal
Operating Loss Carryforwards [Line Items]
Loss carryforwards	$ 60,200,000
Loss carryforwards subject to expiration			$ 9,000,000
Net operating losses expiration year			2037
State
Operating Loss Carryforwards [Line Items]
Loss carryforwards	$ 60,900,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Current per claim coverage	$ 1,000,000
Annual coverage limit	3,000,000
Malpractice insurance accrual incurred	$ 0	$ 0